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57 ABSTRACT 
Disclosed are methods of producing eukaryotic disulfide 
bond-containing polypeptides in bacterial hosts, and com 
positions resulting therefrom. Co-expression of a eukaryotic 
foldase and a disulfide bond-containing polypeptide in a 
bacterial host cell is demonstrated. In particular 
embodiments, the methods have been used to produce 
mammalian pancreatic trypsin inhibitor and tissue plasmi 
nogen activator (tPA) in Soluble, biologically-active forms, 
which are isolatable from the bacterial periplasm. Also 
disclosed are expression Systems, recombinant vectors, and 
transformed host cells. 
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METHODS FOR PRODUCING SOLUBLE, 
BIOLOGICALLY ACTIVE DISULFIDE-BOND 
CONTAINING EUKARYOTIC PROTEINS IN 
BACTERIAL CELLS 
The present application is a continuing application based 
on U.S. Provisional patent application Ser. No. 60/014,950, 
filed Apr. 5, 1996, the entire content of which is specifically 
incorporated herein by reference. 
The United States government has certain rights in the 
present invention pursuant to Grant 1 RO1-GM47520-01A1 
from the National Institutes of Health. 
BACKGROUND OF THE INVENTION 
1.1 Field of the Invention 
The present invention relates generally to the field of 
molecular biology. More particularly, certain embodiments 
concern methods and compositions related to improved 
methods of producing biologically-active, Soluble eukary 
otic disulfide bond-containing eukaryotic polypeptides in 
bacterial cells. In preferred embodiments, disulfide-bond 
containing eukaryotic fusion proteins Such as tissue plasmi 
nogen activator (tPA) and pancreatic trypsin inhibitor (PTI) 
are produced in recombinant transformed Escherichia coli 
cells using recombinant vector Systems which direct the 
co-expression of the eukaryotic protein and a eukaryotic 
foldase, such as protein disulfide isomerase (PDI). 
1.2 Description of the Related Art 
1.2.1 PROTEIN EXPRESSION IN BACTERIAL HOSTS 
A significant achievement in molecular biology has been 
the use of recombinant bacterial cells to produce eukaryotic 
proteins. This method has been particularly useful for pro 
duction of medically important polypeptides that are 
obtained in low yield from natural sources. Often otherwise 
difficult to obtain in quantity, Such proteins are “overex 
pressed” in the host cell and Subsequently isolated and 
purified. Preinsulin for example may be produced in a 
recombinant prokaryotic microorganism carrying DNA 
encoding rat preinsulin (U.S. Pat. Nos. 4,431,740 and 4,652, 
525, specifically incorporated herein by reference). 
Expression of multiple disulfide bond-containing eukary 
otic polypeptides, and particularly mammalian proteins, in 
bacterial cells has frequently produced disappointing and 
unsatisfactory results because conditions and environment 
in the host cells were not conducive to correct folding. 
Disulfide bond formation is a process mainly restricted to 
proteins outside the cytoplasmic compartment Such as those 
secreted into the lumen of the endoplasmic reticulum (ER) 
or the periplasm of gram negative bacteria. Correct folding 
may depend on the formation of cysteine-cysteine linkages 
and Subsequent Stabilization of the protein into an enzymati 
cally active Structure. However, the cytoplasm is in fact a 
reducing environment due to the presence of thioredoxin 
reductase or reduced glutathione, thus blocking oxidation So 
that disulfide bonds do not form. The endoplasmic reticulum 
(ER) apparently is more conducive to oxidation due to the 
presence of oxygen or oxidized glutathione. 
Recent studies indicate that disulfide bond formation in 
Vivo is a catalyzed process, whether in the ER or periplasm. 
In E. coli, a pathway for the formation of disulfide bonds in 
Secreted proteins has been described, involving two proteins, 
DsbA and DsbB (Bardwell et al., 1993; Missiakas et al., 
1993). 
A role for these Dsb proteins is supported by the obser 











defective with respect to disulfide bond formation (Dailey 
and Berg, 1993). In the yeast Saccharomyces cerevisiae, a 
Similar defect is found in certain mutants defective in protein 
disulfide isomerase (PDI) gene. Disulfide bond formation in 
carboxypeptidase Y in these mutants is impaired. 
1.2.2 EXPRESSION OF EUKARYOTIC PROTEINS IN BACTE 
RIAL, HOSTS 
It is known that disulfide bonds are critical in Some 
proteins in order for proper folding and even in transport and 
Secretion. Yet many proteins cannot be efficiently expressed 
in bacterial hosts due to failure of disulfide bond formation. 
Cytoplasmic expression Systems in bacteria are not condu 
cive to disulfide bond formation because of a reducing 
environment. The presence of proteases in the cytoplasm 
may cause rapid degradation of the protein, resulting in low 
yields. 
Most exported proteins contain disulfide bonds which 
confer increased thermodynamic stability to the folded 
polypeptide chain. The Sequence of events involved in 
cysteine oxidation and correct pairing to form native disul 
fide bonds is a critical Step in protein folding. Due to 
constraints related to the reactivity or Structural accessibility 
of cysteine thiols in proteins, disulfide bonds often form very 
Slowly. A complex cellular machinery, whose components 
and mode of action are only now beginning to be 
understood, has evolved to catalyze these processes in Vivo. 
In Gram-negative bacteria Such as E. coli, the cytoplasm is 
highly reducing and therefore disulfide formation normally 
occurs after a polypeptide chain has been translocated acroSS 
the inner membrane (Wilfing and Pluckthun, 1994; 
Bardwell, 1994). Genetic analysis has identified at least six 
genes coding for cell envelope proteins that play a role in 
disulfide bond formation. Four of these proteins have been 
characterized in some detail (Bardwell, 1994; Missiakas et 
al., 1995). DsbA is a 21.5 kDa enzyme having a thioredoxin 
like Subdomain with an extremely reactive and highly oxi 
dizing disulfide bond but poor disulfide isomerization activ 
ity (Bardwell et al., 1991; Kamitani et al., 1992; Zapun et al., 
1993; Wunderlich and Glockshuber, 1993a; 1993b; Joly and 
Swartz, 1994). DsbB is a cytoplasmic membrane protein 
which is required for the reoxidation of DsbA (Guilhot et al., 
1995; Bardwell et al., 1993; Missiakas et al., 1993; Dailey 
and Berg, 1993). DsbC is another soluble cysteine oxi 
doreductase and has much higher disulfide isomerase activ 
ity than DsbA (Bardwell, 1994; Missiakas et al., 1994). 
Finally, the recently discovered DsbD is an inner membrane 
protein which has been proposed to function as a reducing 
Source in the periplasm and to be required for maintaining 
proper redox conditions (Missiakas et al., 1995). 
Bacterial proteins become oxidized and fold rapidly Soon 
after export from the cytoplasm. However, the formation of 
native disulfide bonds in heterologous proteins with multiple 
cysteines is often very inefficient (Wunderlich and 
Glockshuber, 1993a; 1993b; De Sutter et al., 1992). Partially 
folded molecules are highly Susceptible to degradation, thus 
resulting in very low yields (Wilfing and Pluckthun, 1994). 
The shortcomings of the disulfide bond formation machinery 
of E. coli with respect to eukaryotic proteins have been 
illuminated by analyzing the folding pathway of the Bovine 
PTI (BPTI) expressed in the periplasmic space (Ostermeier 
and Georgiou, 1994). BPTI is a 6.5-kDa protease inhibitor 
with three disulfide bonds. In E. coli, just as in vitro, the rate 
limiting Step in folding is the isomerization of two disulfide 
intermediates. The bacterial periplasmic space is thought to 
be strongly oxidizing (Wunderlich and Glockshuber, 1993a; 
1993b; Walker and Gilbert, 1994; Kishigami et al., 1995) 
and appears to lack Sufficient disulfide isomerase activity 
6,027,888 
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required for the folding of heterologous multi-disulfide 
proteins. In Sharp contrast to the bacterial periplasm, disul 
fide bond formation in eukaryotes occurs in the endoplasmic 
reticulum, a compartment which is maintained at relatively 
reducing conditions (Hwang et al., 1992). Disulfide bond 
formation and isomerization in the ER is catalyzed by PDI, 
an abundant 55-kDa enzyme which apart from its 
thioredoxin-like active site shares little homology with 
prokaryotic proteins. PDI contains two active Sites that are 
not functionally equivalent, has been shown to both promote 
and inhibit protein aggregation, and can exist in different 
oligomerization States (Freedman et al., 1994, Lyles and 
Gilbert, 1994; Puig and Gilbert, 1994; Puig et al., 1994). 
1.2.3 CURRENT METHODS OF PRODUCING EUKARYOTIC 
PROTEINS ARE INEFFICIENT 
Expression enhancers for increasing yield of eukaryotic 
proteins expressed in E. coli cells have been reported (U.S. 
Pat. No. 5,336,602). The expression enhancer is simulta 
neously expressed with a protein of interest where the rate 
of expression is shown to increase by comparison with 
expression of the protein of interest in the absence of an 
enhancer. However, while yield is increased over expression 
when enhancer is not present, there are no indications that 
either correct folding is achieved or that full activity is 
obtained. 
Eur. Pat. Appl. No. EP510,658 describes an improvement 
of the yield of secreted disulfide-bonded proteins in bacterial 
cell by providing a simultaneous expression of a recombi 
nant vector encoding the prokaryotic protein disulfide 
isomerase of E. coli and the addition of thiol reagents to the 
culture medium to promote correct folding of the Secreted 
polypeptide of interest. Unfortunately, the method produced 
negligible Secreted protein unless Sufficient thiol reagent was 
added to the culture medium, and if too much thiol reagent 
was present, cells were killed and the total protein isolated 
declined dramatically. 
tPA is one example of a pharmaceutically-important drug 
produced by recombinant methods. Unfortunately the cur 
rent methods for producing tPA from bacterial cell culture 
are both costly and laborious. One such method for the 
production of tRA in heterologous host organisms relies on 
the production of inactive tRA intracellularly in inclusion 
bodies, and the Subsequent isolation and purification of Such 
inclusion bodies, followed by activation of the tRA once 
freed from the inclusion bodies. U.S. Pat. No. 5,077,392 
discloses a renaturation method for refolding denatured 
proteins obtained after expression in inclusion bodies. tRA 
was isolated as a denatured reduced protein and on Subse 
quent oxidation refolded under oxidizing conditions to 
obtain what was reported as up to a 26% yield of “reacti 
vated” protein. While the method appeared to improve 
polypeptide yield, the process involves multiple, time 
consuming Steps, due to the initial recovery of the insoluble, 
inactive protein. 
Other methods of producing tPA have employed eukary 
otic cell culture methods, which are also expensive and 
time-consuming. Mammalian cells have been used in 
attempts to improve production of highly active polypep 
tides such as t?A. U.S. Pat. No. 4,661,453 discloses pro 
duction of tRA in Substantial quantities in rat prostate adeno 
carcinoma cells. The tBA isolated from the cell culture 
medium shows tRA activity, however the method is quite 
expensive Since the mammalian cells have an origin in 
Spontaneous adenocarcinoma cancer cells, and must be 
selected for the ability to produce tRA. The method has not 











proteins Such as t?A on an economic Scale. Even methods 
involving the production of tRA in recombinant chinese 
hamster ovary (CHO) cells, result in a cost-per-unit-dose of 
approximately S1200 in the current pharmaceutical market. 
1.2.4 DEFICIENCIES IN THE PRIOR ART 
Currently there is a lack of efficient methods of producing 
complex eukaryotic proteins with multiple disulfide bonds 
on an economic Scale. Likewise, there is a need to develop 
methods which produce proteins that are correctly folded 
and active without the need for reactivation or Subsequent 
processing once isolated from a host cell. 
Therefore, what is lacking in the prior art are methods, 
recombinant vectors, host cells, and compositions compris 
ing high-level expression of eukaryotic disulfide bond 
containing polypeptides (such as tA and BPTI) which are 
Soluble, correctly-folded, active, and readily isolatable from 
cell extracts of prokaryotic hosts. 
2. SUMMARY OF THE INVENTION 
The present invention overcomes one or more of these 
and other drawbacks inherent in the prior art by providing 
novel methods, recombinant host cells, vectors and compo 
Sitions resulting therefrom for efficiently producing eukary 
otic polypeptides containing disulfide bonds in bacterial host 
cells which are active, correctly folded, and Secreted from 
the bacterial cell to provide economic and convenient means 
for the recovery, isolation, and purification of the recombi 
nant polypeptide of interest. The present invention repre 
Sents a significant breakthrough in the fields of molecular 
biology, protein chemistry, and pharmaceutics, in producing 
eukaryotic recombinant polypeptides in prokaryotic hosts 
through novel methods and recombinant vectors which 
direct the coexpression of eukaryotic polypeptides of inter 
est with a eukaryotic foldase Such as protein disulfide 
isomerase. Recovery of correctly folded, active, Soluble 
recombinant polypeptides in Significant quantity is now 
possible by employing the disclosed methods and compo 
Sitions. 
In one embodiment, the present invention provides a 
process for producing in a bacterial cell, a biologically 
active, Soluble eukaryotic polypeptide having at least about 
three disulfide bonds. The process generally involves 
expressing in the cell a first DNA segment encoding a 
disulfide isomerase operably linked to a Signal Sequence and 
a Second DNA segment encoding a eukaryotic polypeptide 
operably linked to a signal Sequence under conditions effec 
tive to produce the eukaryotic polypeptide. Preferably, the 
polypeptide is a mammalian polypeptide, with human and 
bovine polypeptides being particularly preferred. In impor 
tant embodiments, the eukaryotic polypeptide is a tissue 
plasminogen activator or pancreatic trypsin inhibitor, and 
the disulfide isomerase is protein disulfide isomerase iso 
lated from rat, yeast, or human origin. 
The eukaryotic polypeptide to be produced in the bacterial 
host will preferably comprise at least about three, four or 
five disulfide bonds. Or more preferably, about six, seven, 
eight, or nine disulfide bonds. Or still more preferably, at 
least about ten, eleven, twelve, thirteen, fourteen, fifteen, 
sixteen, or seventeen disulfide bonds. When the eukaryotic 
polypeptide is tRA, the peptide preferably comprises at least 
about seventeen disulfide bonds. 
The Signal Sequence is preferably Selected from the group 
consisting of Ompa, LamB, St, MalE, Lpp, and PelB, with 
Omp A and StI sequences be particularly preferred. Pre 
ferred promoters for the expression of the two DNA seg 
ments are Selected from the group consisting of lac-lipp, lipp, 
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trc, tac, T7, PA, phoA and 2, with lac-lpp promoters 
being particular useful in the practice of the invention. 
Plasmids such as plPPsOmp ArPDI are preferred for the 
expression of the disulfide isomerase, and plasmids Such as 
pTPA177 or pACYCBPTI are particularly desirable for 
expression of the eukaryotic polypeptides of interest. 
The bacterial cell may be cultured in a medium compris 
ing one or more reducing agents Selected from the group 
consisting of glutathione, cysteine, cyStamine, 
thioglycollate, dithiothreitol and dithioerythritol, and 
preferably, the bacterial cell is an Enterobacteriaceae cell 
Such as Escherichia or Salmonella spp. cells. Highly pre 
ferred cells are E. coli ATCC 98.380, SF103, SF110, UT5600 
and RB7911 cells. ATCC 98.380 was deposited on Mar. 28, 
1997 with the American Type Culture Collection, 12301 
Parklawn Drive, Rockville, Md. 20852 in accordance with 
U.S. Patent and Trademark Office requirements for micro 
organism deposits. The deposit has been made in accordance 
with the terms of the Budapest Treaty on the international 
recognition of the deposit of microorganisms for the pur 
poses of patent procedure. In accordance with the terms of 
the Budapest Treaty: (a) the deposit will be made accessible 
to the Commissioner upon request during the pendency of 
this application; (b) all restrictions to access by the public of 
this deposit will be irrevocably removed upon granting of 
the patent; (c) this deposit will be maintained in the public 
depository for a period of thirty years or five years after the 
last request, or for the effective life of the patent, whichever 
is longer; and, (d) this deposit will be replaced if it should 
ever become non-viable. 
An important aspect of the invention is the production in 
bacterial cells of Soluble, biologically-active eukaryotic 
polypeptides. In important embodiments, the Soluble protein 
is Secreted to the periplasm or to the outer membrane of the 
bacterial cell, and the polypeptide is isolatable from a culture 
Supernatant or a Soluble fraction of the bacterial cell. 
Preferably, the eukaryotic polypeptide produced in the bac 
terial host assumes a conformation Substantially identical to 
the conformation assumed by the polypeptide when pro 
duced in a eukaryotic host cell. Preferably, the eukaryotic 
polypeptide produced in the bacterial cell has a specific 
activity equal to or greater than the Specific activity of the 
polypeptide when produced in a eukaryotic host cell. When 
the eukaryotic polypeptide is a tissue plasminogen activator 
protein, a specific activity of at least about 5 to about 12 
ag/1/OD of culture is obtained. This corresponds to a 
specific activity of approximately 2000 to 48000 IU/l/ODoo 
nm. When the eukaryotic polypeptide is a pancreatic trypsin 
inhibitor protein, a Specific activity of about 10 ug/mg of 
total cell protein is obtained. 
A further aspect of the invention is an expression System 
for producing in a bacterial cell, a biologically-active, 
Soluble eukaryotic polypeptide. The expression System gen 
erally comprises a first DNA segment and a second DNA 
Segment, with the first Segment encoding a disulfide 
isomerase and the Second Segment encoding a eukaryotic 
polypeptide having at least about three disulfide bonds. AS 
Stated above, the protein produced is preferably a disulfide 
bond containing polypeptide Such as tissue plasminogen 
activator or pancreatic trypsin inhibitor, and the disulfide 
isomerase is preferably a rat, yeast, or human PDI. The DNA 
Segments preferably further comprise a Signal Sequence Such 
as Omp A, LamB, StI, MalE, Lpp, or PelB, and are 
expressed by a promoter Such as lac-lpp, ara, lac, lpp, trc, 
tac, T7, PA, phoA or 2. Preferred examples of the 
expression system include plPPsOmp ArPDI co-expressed 











bacterial cell may be cultured in a medium comprising one 
or more reducing agents Selected from the group consisting 
of glutathione, cysteine, cyStamine, thioglycollate, dithio 
threitol and dithioerythritol, and preferably, the bacterial cell 
is an Enterobacteriaceae cell Such as Escherichia or Salmo 
nella spp. cells. Highly preferred cells are E. coli ATCC 
98380, SF103, SF110, UT5600 and RB7911 cells. 
Preferably the eukaryotic polypeptide expressed by this 
System has a specific activity of at least about 1 to about 
1000 ug/l/ODoo of culture, or more preferably, about 5 
to about 500 ug/l/ODoo of culture, or more preferably, 
about 10 to about 100 ug/l/ODoo of culture, with Specific 
activities in the range of at least about 5 to about 12 
ag/l/OD units of culture being highly preferred. 
The expression System may comprise a single recombi 
nant vector which expresses both the disulfide isomerase 
encoding DNA segment and the polypeptide of interest 
encoding Second DNA segment. Alternatively, the 
expression System may comprise two or more distinct plas 
mids one of which expresses the first DNA segment and a 
Second of which expresses the Second DNA segment. In the 
case of the latter arrangement, it is preferably that both 
vectors are capable of replication and expression in a single 
bacterial cell. An example of Such as System is a bacterial 
cell comprising the vectorp PPsOmpArPDI in combination 
with a second vector such as pACYCBPTI or pTPA177. 
A further aspect of the invention is a recombinant vector 
comprising a first transcriptional unit encoding a mamma 
lian protein disulfide isomerase operably linked to a first 
Signal Sequence and a Second transcriptional unit comprising 
a DNA segment encoding a mammalian polypeptide having 
at least about three disulfide bonds operably linked to a 
Second signal Sequence. 
AS Stated above, the protein produced is preferably a 
disulfide-bond containing polypeptide Such as tissue plas 
minogen activator or pancreatic trypsin inhibitor, and the 
disulfide isomerase is preferably a rat, yeast, or human PDI. 
The DNA segments preferably further comprise a signal 
sequence such as Omp A, LamB, St, MalE, Lpp, or PelB, 
and are expressed by a promoter Such as lac-lipp, ara, lac, 
lpp, trc, tac, T7, PA, phoA or 2. Preferred examples of 
the recombinant vectors include plPPsOmp ArPDI, 
pTPA177 and pACYCBPTI. The vectors are preferably 
introduced and maintained in a bacterial cell which may be 
cultured in a medium comprising one or more reducing 
agents Selected from the group consisting of glutathione, 
cysteine, cystamine, thioglycollate, dithiothreitol and 
dithioerythritol, and preferably, the bacterial cell is an 
Enterobacteriaceae cell Such as Escherichia or Salmonella 
spp. cells. Highly preferred cells are E. coli ATCC 98.380, 
SF103, SF110, UT5600 and RB7911 cells. 
AS Such, a recombinant host cell transformed with an 
expression System or vector described above is a further 
embodiment of the invention. Preferred examples of the 
recombinant host cell include ATCC 98.380, and SF103, 
SF110, UT5600 or RB7911 cells transformed with the 
recombinant vector p PPSOmpArPDI as well as either of 
plasmids pTPA177 or pACYCBPTI. 
A further aspect of the invention is a composition com 
prising a biologically-active, Soluble, recombinant tissue 
plasminogen activator protein or peptide operably linked to 
a bacterial export Signal peptide. Preferably the tissue plas 
minogen activator is a mammalian tissue plasminogen acti 
Vator Such as human tPA. In particular aspects, the compo 
Sition comprises a bacterial export Signal peptide Selected 
from the group consisting of Omp A, LamB, St, MalE, Lpp, 
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and PelB. In preferred embodiments, the tRA is encoded by 
a DNA segment positioned under the control of a promoter 
Selected from the group consisting of lac-lpp, lipp, trc, tac, 
T7, PA, phoA and 2 p. 
Preferably the tPA composition has a specific activity of 
at least about 1 to about 1000 ug/l/ODoo of culture, or 
more preferably, about 5 to about 500 lug/l/ODoo of 
culture, or more preferably, about 10 to about 100 ug/l/ 
ODoo of culture, with Specific activities in the range of 
at least about 5 to about 12 tug/l/ODoo units of culture 
being highly preferred. 
A further aspect of the invention is a composition com 
prising a biologically-active, Soluble, recombinant pancre 
atic trypsin inhibitor protein or peptide operably linked to a 
bacterial export Signal peptide. Preferably the pancreatic 
trypsin inhibitor protein is a mammalian pancreatic trypsin 
inhibitor protein such as human or bovine PTI. In particular 
aspects, the composition comprises a bacterial export Signal 
peptide Selected from the group consisting of Omp A, LamB, 
StII, MalE, Lpp, and PelB. In preferred embodiments, the 
PTI is encoded by a DNA segment positioned under the 
control of a promoter Selected from the group consisting of 
lac-lpp, pp, tre, tac, T7, PAD, phoA and 2 p. 
Preferably the PTI composition has a specific activity of 
at least about 1 to about 1000 ug/l/ODoo of culture, or 
more preferably, about 5 to about 500 lug/l/ODoo of 
culture, or more preferably, about 10 to about 100 ug/l/ 
ODoo of culture, with Specific activities in the range of 
at least about 5 to about 12 tug/l/ODoo units of culture 
being highly preferred. 
These and other embodiments of the invention are further 
understood in light of the teaching herein. 
2.1 METHODS FOR PRODUCING EUKARYOTICPOLYPEPTIDES IN 
BACTERIAL CELLS 
The present invention discloses methods for producing 
recombinant multi-disulfide polypeptides such as PTI, tRA, 
antibody fragments, protease inhibitors, therapeutic 
enzymes, lymphokines, neurotrophic factors, and related 
polypeptides and derivatives, mutants, and fusion proteins 
derived therefrom. One of the problems with t?A isolated 
from natural Sources is low yields and extensive purification 
processes. The present invention in an important embodi 
ment illustrates a Strategy for overproducing tPA from a 
bacterial host, employing DNA constructs encoding human 
tPA and rat PDI to transform Gram-negative bacterial cells 
and coexpress the two proteins to produce active, Soluble, 
secreted recombinant tPA polypeptides in vivo. In addition 
to the production of the complete tRA molecule, derivatives 
of tRA lacking the finger-like region, one or both of the 
kringle Sub-domains or the epidermal growth factor Subdo 
main may also be expressed in functional form. Such 
mutants as well as mutated tRA molecules with amino acid 
substitutions that affect the proteolytic activity exhibit useful 
pharmacological and/or pharmacokinetic properties, and are 
all contemplated to fall within the Scope of the present 
invention. 
An important aspect of the invention concerns methods 
for producing a biologically-active, recombinant eukaryotic 
polypeptide that contains multiple disulfide bonds. The 
method involves co-expressing in a Suitable prokaryotic cell, 
Such as a bacterial cell, a DNA segment encoding a prokary 
otic Signal Sequence-eukaryotic disulfide isomerase fusion 
protein and a DNA segment encoding a prokaryotic Signal 
Sequence-eukaryotic recombinant polypeptide fusion pro 
tein under Suitable physiological conditions to produce the 
recombinant eukaryotic fusion protein of interest. It is 












eukaryotic protein for which expression in a prokaryotic 
host is desirable, but in particular, eukaryotic proteins which 
contain two or more disulfide bonds, and preferably those 
which contain at least three or four disulfide bonds or more. 
Such preferred recombinant polypeptides include mam 
malian tissue plasminogen activator, mammalian pancreatic 
trypsin inhibitor, antibody fragments, insulin, protease 
inhibitors, therapeutic enzymes, lymphokines, cytokines, 
growth factors, neurotrophic factors and the like. The 
polypeptides may be native or mutated polypeptides, and 
preferred Sources for Such mammalian polypeptides include 
human, bovine, equine, porcine, lupine, and rodent Sources, 
with human proteins being particularly preferred. The dis 
ulfide isomerase may be any Such eukaryotic foldase which 
is capable of isomerizing disulfide bonds in a prokaryotic 
host. One Such isomerase which is particularly preferred is 
mammalian protein disulfide isomerase. Most preferably, 
rat, human, bovine or porcine protein disulfide isomerases 
are contemplated to be useful in the practice of the inven 
tion. 
The Signal Sequence employed in the practice of the 
invention may be any Such Sequence which encodes a signal 
capable of directing the export of the fusion protein to the 
bacterial periplasm or Outer membrane, or alternatively into 
the culture Supernatant in which Such cells are grown. 
Typically, the Signal Sequence, or leader peptide, may be any 
of those well-known to those of skill in the art to be capable 
of directing the export of proteins in Vivo in bacterial cells. 
A particularly preferred Sequence is the E. coli alkaline 
phosphatase Omp A Signal Sequence, but equally preferred 
signal sequences include the Lipp, LamB, MalE, PelB or StI 
Signal Sequences and the like. 
2.2 EXPRESSION SYSTEMS FOR PRODUCING EUKARYOTIC 
POLYPEPTIDES IN BACTERIA 
In another preferred embodiment, the invention concerns 
an expression System that expresses both a disulfide 
isomerase Such as one of the disulfide isomerases described 
herein, and an eukaryotic recombinant polypeptide of inter 
est. The expression System has been used to produce recom 
binant OmpA-tPA and OmpA-BPTI when the OmpA-PDI 
polypeptide was coexpressed in the same recombinant host 
cells. The expression System is useful in the expression of 
recombinant polypeptides which have multiple disulfide 
bonds, even up to and including those with fourteen disulfide 
bonds. 
The expression System in a general Sense is composed of 
two expression units: one containing a DNA segment which 
encodes the disulfide isomerase fusion protein, and a Second 
unit containing a DNA segment which encodes the recom 
binant fusion protein of interest. As described above, the two 
expression units may either be contained on a single recom 
binant vector, or alternatively, may be contained on two 
Separate and distinct recombinant vectors. In the case of the 
latter, any two recombinant vectors may be utilized So long 
as the replicons are compatible in the Same host cell and that 
the expression unit of each vector functions in the same cell 
to permit the co-expression of the two expression units. For 
example, the inventors contemplate the coexpression of 
pLPPsOmpArPDI and pACYCBPTI to be particularly use 
ful in the production of BPTI from bacterial host cells, and 
the coexpression of plPPsOmpArPDI and pTPA177 to be 
particularly useful in the production of tRA from bacterial 
host cells. 
Expression of the fusion proteins may be promoted by any 
of a number of Suitable promoter Sequences which are 
well-known to promote the transcription of genes and/or 
operons in bacterial cells. In preferred embodiments, the 
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DNA segments of the present invention are expressed from 
a lac-lpp, tac, ara, lac, trc, PhoA PA, ), lipp, or T7 
promoter. The components of the expression System 
described herein may be located on Separate recombinant 
vectors with each transcriptional unit under the control of its 
own promoter, or alternatively, the components of the 
expression System may be located within a Single recombi 
nant vector. In the latter case, the disulfide isomerase 
encoding transcriptional unit may be controlled by one 
promoter, while the recombinant disulfide bond-containing 
polypeptide-encoding transcriptional unit may be controlled 
by a separate promoter, or alternatively, the two transcrip 
tional units may be in the form of a “tandem' transcriptional 
unit with both being controlled by a Single promoter located 
5' of both coding regions. The inventors have found the 
lac-lpp promoter to be particularly useful in the practice of 
the present invention. 
Once a suitable (full length if desired) clone or clones 
have been obtained, whether they be CDNA based or 
genomic, one may proceed to prepare an expression System 
for the recombinant preparation of the eukaryotic polypep 
tides of the present invention. The engineering of DNA 
Segment(s) for expression in a prokaryotic or eukaryotic 
System may be performed by techniques generally known to 
those of skill in recombinant expression. It is believed that 
expression in bacterial hosts, and E. coli in particular, will be 
preferred in the expression of high levels of correctly folded, 
active, Soluble disulfide bond-containing eukaryotic 
polypeptides. 
The cDNAs for such foldases and disulfide-containing 
proteins of interest may be separately expressed in bacterial 
Systems, with the encoded proteins being expressed as 
fusions with f3-galactosidase, ubiquitin, SchistoSoma japoni 
cum glutathione S-transferase, and the like. It is believed 
that bacterial expression using the methods described will 
ultimately have advantages over present prokaryotic expres 
Sion Systems which produce limited quantities of the pro 
teins of interest intracellularly, inactive, in the form of 
inclusion bodies. This is particularly true for preparations of 
recombinant tBA. 
It is proposed that transformation of host cells with DNA 
Segments encoding the foldase (such as PDI) and the protein 
of interest will provide a convenient means for obtaining 
high levels of active Secreted polypeptide. However, Sepa 
rate expression followed by reconstitution or reactivation of 
the protein once Secreted is also certainly within the Scope 
of the invention. For example, the inventors contemplate 
that the extracellular addition of thiol reagents Such as 
glutathione will be useful in enhancing the recovery of 
certain proteins in large quantity using the methods 
described herein. Both cDNA and genomic Sequences are 
Suitable for expression, as the host cell will, of course, 
process the genomic transcripts to yield functional mRNA 
for translation into protein. 
For expression in this manner, one would position the 
coding Sequences adjacent to and under the control of the 
promoter. It is understood in the art that to bring a coding 
Sequence under the control of Such a promoter, one positions 
the 5' end of the transcription initiation site of the transcrip 
tional reading frame of the protein between about 1 and 
about 50 nucleotides “downstream” of (i.e., 3' of) the chosen 
promoter. 
In accordance with the general guidelines described 
above, a preferred method for expressing human t?A DNA 
has been found to be the transformation of E. coli SF103 
cells with the expression vectors termed pTPA177 and 











structed from paCYC184, and contains the Omp A leader 
tPA gene fusion. 
Likewise, a preferred method for expressing bovine PTI 
DNA has been found to be the transformation of E. coli 
SF103 cells with the expression vectors termed paCY 
CBPTI and pLPPsOmpArPDI. The paCYCBPTI expres 
sion vector is constructed from paCYC184, and contains 
the Omp A leader-BPTI gene fusion. 
pIPPsOmp ArPDI contains the gene for the mature rat 
PDI fused to the Omp A signal sequence under the control of 
the lipp-lac promoter. 
Preferred expression Systems for the production of recom 
binant proteins may be contained either on a Single plasmid 
vector containing the isomerase and disulfide. 
It is contemplated that the recombinant polypeptides of 
the invention may be "overexpressed”, i.e., expressed in 
increased levels relative to its natural expression in eukary 
otic cells, or even relative to the expression of other proteins 
in the recombinant prokaryotic host cells. Such overexpres 
Sion may be assessed by a variety of methods, including 
radio-labeling and/or protein purification. However, Simple 
and direct methods are preferred, for example, those involv 
ing SDS/PAGE and protein staining or Western blotting, 
followed by quantitative analyses, Such as densitometric 
Scanning of the resultant gel or blot. A specific increase in 
the level of the recombinant protein or peptide in compari 
son to the level in native cells is indicative of 
overexpression, as is a relative abundance of the Specific 
protein in relation to the other proteins produced by the host 
cell and, e.g., Visible on a gel. 
As used herein, the term “engineered” or “recombinant” 
cell is intended to refer to a cell into which a recombinant 
gene, Such as a gene encoding the foldase along With a gene 
encoding a disulfide bond-containing polypeptide of interest 
(e.g., tRA or BPTI) have been introduced. Therefore, engi 
neered cells are distinguishable from naturally occurring 
cells which do not contain a recombinantly introduced gene. 
Engineered cells are thus cells having a gene or genes 
introduced through the hand of man. Recombinantly intro 
duced genes will either be in the form of a cDNA gene (i.e., 
they will not contain introns), a copy of a genomic gene, or 
will include genes positioned adjacent to a promoter not 
naturally associated with the particular introduced gene. 
Generally Speaking, it may be more convenient to employ 
as the recombinant gene a cDNA version of the gene. It is 
believed that the use of a cDNA version will provide 
advantages in that the size of the gene will generally be 
much Smaller and more readily employed to transfect the 
targeted cell than will a genomic gene, which will typically 
be up to an order of magnitude larger than the cDNA gene. 
However, the inventors do not exclude the possibility of 
employing a genomic version of a particular gene where 
desired. 
Where the introduction of a recombinant version of one or 
more of the foregoing genes is required, it will be important 
to introduce the gene Such that it is under the control of a 
promoter that effectively directs the expression of the gene 
in the cell type chosen for engineering. In general, one will 
desire to employ a promoter that allows constitutive 
(constant) expression of the gene of interest. Commonly 
used constitutive promoters are generally viral in origin, and 
include the cytomegalovirus (CMV) promoter, the Rous 
Sarcoma long-terminal repeat (LTR) sequence, and the SV40 
early gene promoter. The use of these constitutive promoters 
will ensure a high, constant level of expression of the 
introduced genes. The inventors have noticed that the level 
of expression from the introduced gene(s) of interest can 
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vary in different clones, probably as a function of the 
particular recombinant gene construct used. Thus, the level 
of expression of a particular recombinant gene can be 
chosen by evaluating different clones derived from each 
transformation Study; once that line is chosen, the constitu 
tive promoter ensures that the desired level of expression is 
permanently maintained. 
2.3 RECOMBINANT VECTORS FOR EXPRESSING EUKARYOTIC 
POLYPEPTIDES IN BACTERIA 
In a related embodiment, the invention discloses a recom 
binant vector comprising a first transcriptional unit encoding 
a mammalian protein disulfide isomerase operatively linked 
to a signal Sequence and a Second transcriptional unit 
comprising a DNA segment encoding a mammalian tissue 
plasminogen activator or a mammalian pancreatic trypsin 
inhibitor. 
A preferred plasmid for the expression of a protein 
disulfide isomerase transcriptional unit is plPPsOmpArPDI. 
A preferred plasmid for cloning the eukaryotic "target' 
polypeptide-encoding DNA fragment is paCYC184, 
although any other vector which may be maintained in the 
bacterial host and is compatible with the PDI-encoding 
expression vector may also be used. In particular, 
pACYC184 was used to create pACYCBPTI and pTPA177 
which contain DNA sequences encoding bovine pancreatic 
trypsin inhibitor and human tissue plasminogen activator, 
respectively. 
2.4 RECOMBINANT HOST CELLS 
In particular, the invention provides recombinant Gram 
negative host cells, preferably E. coli or Salmonella spp., 
transformed with nucleic acid Segments encoding eukaryotic 
disulfide bond-containing polypeptides and an eukaryotic 
foldase from which the correctly-folded, active disulfide 
bond-containing polypeptide may be isolated. In Sharp con 
trast to native un-engineered host cells, these transformed 
host cells have the ability to catalyze the formation and 
isomerization of disulfide bonds in eukaryotic proteins. 
Wild-type unengineered bacteria cannot normally form the 
correct folded Structure of these proteins due to an inability 
to isomerize disulfide bonds in eukaryotic proteins. 
The foldase is preferably a disulfide isomerase, and more 
preferably a protein disulfide isomerase. Such PDIs may be 
isolated from mammalian cells, plant cells, mycelial fungi, 
or yeast cells. Eukaryotic foldases Such as the yeast Eug1 
and its homologs are also contemplated to be useful in the 
practice of the present invention. Particularly preferred 
eukaryotic PDIs are obtained from mammalian or yeast 
Sources. Exemplary mammalian Sources for the foldases 
include human, bovine, rodent, porcine, equine, and lupine 
mammals. Exemplary yeast Sources for the foldases include 
Saccharomyces spp. Pichia spp. (in particular Pichia 
pastoris) and Candida spp. 
Prokaryotic hosts are preferred for expression of the 
proteins of the present invention. Some examples of 
prokaryotic hosts are E. coli strain SF103, RR1, LE392, B, 
'77 (ATCC 31537) as well as E. coli W3110 (F, ), 
prototrophic, ATCC 273325). Enterobacteriaceae species 
Such as Salmonella typhimurium and Serratia marceScens, 
and various Pseudomonas Species may also be used. 
In general, plasmid vectors containing replicon and con 
trol Sequences which are derived from Species compatible 
with the host cell are used in connection with these hosts. 
The vector ordinarily carries a replication site, as well as 
marking Sequences which are capable of providing pheno 
typic Selection in transformed cells. For example, E. coli is 
typically transformed using pBR322, a plasmid derived 











as described above. p3R322 contains genes for amplicillin 
(Amp) and tetracycline (Tet) resistance and thus provides 
easy means for identifying transformed cells. pBR322, its 
derivatives, or other microbial plasmids or bacteriophage 
may also contain, or be modified to contain, promoters 
which can be used by the microbial organism for expression 
of endogenous proteins. 
In addition, phage vectors containing replicon and control 
Sequences that are compatible with the host microorganism 
can be used as transforming vectors in connection with these 
hosts. For example, bacteriophage such as GEMTM-11 may 
be utilized in making a recombinant vector which can be 
used to transform Susceptible host cells Such as E. coli 
LE392. 
Those promoters most commonly used in recombinant 
DNA construction include the f-lactamase (penicillinase) 
and lactose promoter Systems (Chang et al., 1978, Itakura et 
al., 1977; Goeddel et al., 1979) or the tryptophan (trp) 
promoter system (Goeddelet al., 1980). While these are the 
most commonly used, other microbial promoters have been 
discovered and utilized, and details concerning their nucle 
otide Sequences have been published, enabling a skilled 
worker to ligate them functionally with plasmid vectors. 
In addition to prokaryotes, eukaryotic microbes, Such as 
yeast cultures may also be employed in various aspects of 
the present invention. Saccharomyces cerevisiae, or com 
mon baker's yeast is the most commonly used among 
eukaryotic microorganisms, although a number of other 
Strains are commonly available. For expression in 
Saccharomyces, the plasmid YRp7, for example, is com 
monly used (Stinchcomb et al., 1979; Kingsman et al., 1979; 
Tschemper et al., 1980). This plasmid already contains the 
trpL gene which provides a Selection marker for a mutant 
Strain of yeast lacking the ability to grow in tryptophan, for 
example ATCC 44076 or PEP4-1 (Jones, 1977). The pres 
ence of the trpL lesion as a characteristic of the yeast host 
cell genome then provides an effective environment for 
detecting transformation by growth in the absence of tryp 
tophan. 
Suitable promoting Sequences in yeast vectors include the 
promoters for 3-phosphoglycerate kinase (Hitzeman et al., 
1980) or other glycolytic enzymes (Hess et al., 1968; 
Holland et al., 1978), such as enolase, glyceraldehyde-3- 
phosphate dehydrogenase, hexokinase, pyruvate 
decarboxylase, phosphofructokinase, glucose-6-phosphate 
isomerase, 3-phosphoglycerate mutase, pyruvate kinase, tri 
oSephosphate isomerase, phosphoglucose isomerase, and 
glucokinase. In constructing Suitable expression plasmids, 
the termination Sequences associated with these genes are 
also ligated into the expression vector 3' of the Sequence 
desired to be expressed to provide polyadenylation of the 
mRNA and termination. Other promoters, which have the 
additional advantage of transcription controlled by growth 
conditions are the promoter region for alcohol dehydroge 
nase 2, isocytochrome C, acid phosphatase, degradative 
enzymes associated with nitrogen metabolism, and the 
a fore mentioned glyceraldehyde-3-phosphate 
dehydrogenase, and enzymes responsible for maltose and 
galactose utilization. Any plasmid vector containing a yeast 
compatible promoter, an origin of replication, and termina 
tion Sequences is Suitable. 
2.5 ISOLATION OF SOLUBLE EUKARYOTIC POLYPEPTIDES FROM 
BACTERIAL CELLS 
Another aspect of the invention concerns the isolation of 
biologically-active recombinant eukaryotic disulfide bond 




The inventors have demonstrated that methods described 
herein may result in Secretion of the recombinant fusion 
polypeptides to the bacterial periplasmic space. It is also 
contemplated that particular gene constructs may be utilized 
which alternatively direct the export of the fusion proteins of 
interest to either the Outer membrane or even result in the 
Secretion of the fusion proteins to the culture Supernatant, 
from which the particular polypeptides may be isolated 
using conventional techniques for the isolation and purifi 
cation of proteins. Particularly preferred cells for use in the 
practice of the invention include Gram-negative Species, and 
in particular, members of the Enterobacteriaceae, with E. 
coli and Salmonella spp. cells being particularly preferred. 
Most preferred strains for use in the practice of the invention 
include E. coli strains such as SF103, SF110, UT5600, or 
RB791 (as disclosed in U.S. Pat. No. 5,508,192, specifically 
incorporated herein by reference). 
The invention also provides for compositions comprising 
a biologically-active, tissue plasminogen activator opera 
tively linked to a bacterial export Signal peptide, and com 
positions comprising a biologically-active, pancreatic 
trypsin inhibitor operatively linked to a bacterial export 
Signal peptide. 
Using the methods disclosed herein, the inventors have 
developed novel compositions comprising a Soluble 
biologically-active tissue plasminogen activator operatively 
linked to a bacterial export Signal peptide which has a 
specific activity of 5-30 ug/L/ODoo unit of culture. The tRA 
composition obtained was isolatable from the bacterial peri 
plasm. 
2.6 PURIFICATION OF EUKARYOTIC PROTEINS FROM THE BAC 
TERIAL PERIPLASM 
Because wild-type prokaryotic hosts lack the appropriate 
enzymes to perform isomerization, and because native bac 
teria cannot Secrete properly folded and active forms of 
eukaryotic polypeptides, a significant limitation in the puri 
fication of valuable recombinant proteins has existed. The 
present invention, however, overcomes limitations in the art 
by providing recombinant host cells which produce 
correctly-folded, biologically-active eukaryotic proteins in 
Soluble, Secreted form. 
The recombinant proteins of the present invention may 
contain multiple disulfide bonds. Particularly preferred are 
proteins which contain at least three disulfide bonds or more. 
More particularly, preferred proteins include those eukary 
otic proteins which contain at least about five or more, or 
even twelve or more, or most preferably even about fourteen 
to about seventeen or more disulfide bonds. The inventors 
have demonstrated Success with the method expressing 
proteins having fewer than four disulfide bonds (Such as 
mammalian pancreatic trypsin inhibitor), and Surprisingly 
have demonstrated Success with proteins having fourteen or 
more disulfide bonds, Such as mammalian tPA. 
Surprisingly, the inventors have determined that the cor 
rect formation of disulfide bonds in proteins of interest can 
be mediated by engineering prokaryotic host cells to express 
an eukaryotic foldase (and in particular disulfide isomerases) 
in conjunction with the Specific eukaryotic protein of interest 
which contain disulfide bonds. This co-expression of a 
foldase enzyme and the disulfide bond-containing peptide of 
interest now permits the efficient production of active pep 
tides in recombinant bacterial host cells. 
By expressing eukaryotic foldases, and particularly dis 
ulfide isomerases, in bacteria concomitantly with nucleic 
acid Segments encoding particular recombinant proteins of 
interest, yields of the recombinant eukaryotic proteins by 











In preferred embodiments, the novel methods disclosed 
herein have employed bacterial cells Such as E. coli to 
produce high yields of multi-disulfide bond-containing 
eukaryotic enzymes. For example, the inventors have Suc 
ceeded in producing significant quantities of active, cor 
rectly folded tRA in a bacterial cell. This protein has 14 
disulfide bonds that must form correctly in order for the 
protein to be active. The invention is the first demonstration 
of production of Significant quantities of tRA from bacterial 
host cells which is not associated with insoluble intracellular 
inclusion bodies. Likewise, the invention has been used to 
facilitate the production of another commercially important 
enzyme, pancreatic trypsin inhibitor, and in particular, 
bovine PTI, using bacterial hosts which co-express an 
eukaryotic foldase such as PDI. The invention represents a 
breakthrough in the production of commercial quantities of 
Such multi-disulfide bond-containing proteins of economic 
interest by providing rapid, inexpensive methodologies for 
Secretion of Such proteins by the engineered bacterial cells. 
In another preferred embodiment, the invention has dem 
onstrated that recombinant host cells devoid of intrinsic 
prokaryotic PDI-like activity may be successfully comple 
mented using the eukaryotic foldase-encoding nucleic acid 
compositions disclosed herein. The inventors have demon 
strated that both rat and yeast-derived PDI-encoding DNA 
Segments may be used to provide disulfide bond isomerizing 
activity to bacterial Strains devoid of Such activity. 
Further aspects of the present invention concern the 
purification, and in particular embodiments, the Substantial 
purification, of a disulfide bond-containing polypeptide, and 
in particular a purified tRA or purified PTI protein compo 
sition. The term “purified tRA” as used herein, is intended to 
refer to a tRA composition, isolatable from recombinant 
bacterial host cells, wherein the tRA is purified to any degree 
relative to its naturally-obtainable state, i.e., in this case, 
relative to its purity within a cell extract. A purified tBA 
composition therefore also refers to a tpA polypeptide, free 
from the environment in which it may naturally occur or 
from the recombinant host cell in which it was produced. 
Likewise, the term “purified PTI' as used herein, is intended 
to refer to a PTI composition, isolatable from recombinant 
bacterial host cells, wherein the PTI is purified to any degree 
relative to its naturally-obtainable State, i.e., in this case, 
relative to its purity within a cell extract. A purified PTI 
composition therefore also refers to a PTI polypeptide, free 
from the environment in which it may naturally occur or 
from the recombinant host cell in which it was produced. 
Generally, “purified” will refer to a tRA or PTI polypep 
tide composition which has been Subjected to fractionation 
to remove various recombinant host cell components, and 
which composition substantially retains its t?A or PTI activ 
ity. Where the term “substantially purified” is used, this will 
refer to a composition in which the protein of interest forms 
the major component of the composition, Such as constitut 
ing about 25%, about 50%, or even about 75% or greater of 
the soluble proteins isolated from the periplasm of the 
recombinant host cells described herein. 
Various methods for quantifying the degree of purification 
of such peptides will be known to those of skill in the art in 
light of the present disclosure. These include, for example, 
determining the Specific activity of an active fraction, or 
assessing the number of polypeptides within a fraction by 
SDS/PAGE analysis. For example, a preferred method for 
assessing the purity of a tpA composition is to calculate the 
Specific activity of the fraction containing the tRA 
composition, to compare it to the Specific activity of the 
initial Soluble protein extract, and to thus calculate the 




AS is generally known in the art, to determine the Specific 
activity, one would calculate the number of units of activity 
per milligram of total protein. In the purification procedure, 
the Specific activity of the Starting material, i.e., of the 
Soluble periplasmic extract, would represent the Specific 
activity of the protein of interest in its un-purified State. At 
each Step in the purification and concentration of the protein 
of interest, one would generally expect the Specific activity 
of the particular enzyme to increase above this value, as it 
is purified relative to its un-purified State. In preferred 
embodiments, it is contemplated that one would assess the 
degree of purity of a given periplasmic fraction comprising 
recombinant tPA or PTI by comparing its specific activity to 
the Specific activity of the Starting material, and representing 
this as X-fold purification. The use of “fold purification” is 
advantageous as the purity of an inhibitory fraction can thus 
be compared to another despite any differences which may 
exist in the actual units of activity or Specific activity. 
Generally, “purified” will refer to a protein or polypeptide 
composition which has been Subjected to fractionation to 
remove various non-peptide components Such as other cell 
components. Various techniques Suitable for use in protein 
purification will be well known to those of skill in the art. 
These include, for example, precipitation with ammonium 
sulfate, PEG, antibodies and the like or by heat denaturation, 
followed by centrifugation; chromatography StepS. Such as 
ion exchange, gel filtration, reverse phase, hydroxylapatite 
and affinity chromatography; isoelectric focusing, gel elec 
trophoresis, and combinations of Such and other techniques. 
AS mentioned above, although preferred for use in certain 
embodiments, there is no general requirement that the 
recombinant polypeptides always be provided in their most 
purified State. Indeed, it is contemplated that less Substan 
tially purified polypeptides, which are nonetheless enriched 
in activity relative to the natural state, will have utility in 
certain embodiments. Partially purified disulfide bond 
containing recombinant polypeptide fractions for use in Such 
embodiments may be obtained by Subjecting a recombinant 
host cell periplasmic fraction to one or a combination of the 
purification Steps commonly used for their purification from 
Soluble fractions as described above. 
2.7 NUCLEIC ACID SEGMENTS ENCODING EUKARYOTIC 
FUSION POLYPEPTIDES 
The process of Selecting and preparing a nucleic acid 
Segment which includes the preferred nucleic acid Sequences 
encoding the peptides of interest is well-known to those of 
skill in the art. This may alternatively be described as 
preparing a nucleic acid fragment, or cloning a specific gene. 
Of course, fragments may also be obtained by other tech 
niques Such as, e.g., by mechanical shearing or by restriction 
enzyme digestion. Small nucleic acid Segments or fragments 
may be readily prepared by, for example, directly Synthe 
sizing the fragment by chemical means, as is commonly 
practiced using an automated oligonucleotide Synthesizer. 
Also, fragments may be obtained by application of nucleic 
acid reproduction technology, such as the PCRTM technology 
of U.S. Pat. Nos. 4,683,195 and 4,683.202 (incorporated 
herein by reference), by introducing Selected Sequences into 
recombinant vectors for recombinant production, and by 
other recombinant DNA techniques generally known to 
those of skill in the art of molecular biology. 
3. BRIEF DESCRIPTION OF THE DRAWINGS 
The drawings form part of the present Specification and 
are included to further demonstrate certain aspects of the 
present invention. The invention may be better understood 











tion with the detailed description of specific embodiments 
presented herein. 
FIG. 1. Expression of rPDI in a disbA mutant. Bacterial 
cultures JCB570 (dsbA) and JCB571 (dsbA) were grown 
overnight at 37 C. and diluted 100 fold into fresh media. 
After 30 min, the cultures were divided in two equal parts, 
one of which received IPTG at a final concentration of 0.5 
mM. Cells were harvested at ODoo =0.4 and fractionated 
by osmotic shock. electrophoresis on the OSmotic shock 
Supernatant was carried out on 12.5% acrylamide gels under 
reducing conditions. The rPDIf fragment, which represents 
a C-terminal fragment of rPDI including the second active 
Site, arises due to an internal translation initiation within rpdi 
(De Sutter et al., 1994). 
FIG. 2A. rPDI rescues phenotypes of dsbA mutants. 
F-pilus assembly. Uninduced cells were either infected with 
the filamentous phage JB4 (Cm M13) or used as the donor 
for conjugation with SF103 as the recipient. Strains: w.t.= 
JCB502F'; disbAT =JCB572 F"; Plasmids: rPDI= 
pLPPsOmpArPDI; control=pTI103. Data represent the aver 
age from three independent Studies. 
FIG. 2B. rPDI rescues phenotypes of dsbA mutants. 
Growth in M9 minimal media. Solid symbols: JCB570 
(dsbA"), open symbols: JCB571 (dsbA); (O,O)=no 
plasmid, (A.A)=pl PPsOmpArPDI, (,D)=pTI103 (control 
plasmid). 
FIG. 3A. Shown is the rPDI rescue of disulfide formation 
in disbA cells. Oxidation of alkaline phosphatase indsbA. 
and disbB cells with or without rPDI. Bacterial cultures 
JCB570 (dsbA' disbB), JCB571 (dsbA disbB) JCB789 
(dsbA" disbB) and JCB758 (dsbA disbB) were labeled 
with S-TRANSLABEL for 45 sec. followed by a 10 min 
chase with exceSS methionine and cysteine. Proteins were 
precipitated with 10% trichloroacetic acid, treated with 
iodoacetamide and immunoprecipitated with antisera 
against alkaline phosphatase. Immune complexes were 
resolved by electrophoresis under non-reducing or reducing 
conditions and Visualized by autoradiography. The positions 
of reduced (red-AP), oxidized (ox-AP) and precursor (pre 
AP) are indicated. 
FIG. 3B. Shown are the effects of rPDI on disulfide 
formation indsbB cells. Oxidation of alkaline phosphatase 
in disbA and disbB cells with or without rPDI. Bacterial 
cultures JCB570 (dsbA" disbB), JCB571 (dsbA disbB) 
JCB789 (dsbA" disbB) and JCB758 (dsbA disbB) were 
labeled with S-TRANSLABEL for 45 sec. followed by a 
10 min chase with exceSS methionine and cysteine. Proteins 
were precipitated with 10% trichloroacetic acid, treated with 
iodoacetamide and immunoprecipitated with antisera 
against alkaline phosphatase. Immune complexes were 
resolved by electrophoresis under non-reducing or reducing 
conditions and Visualized by autoradiography. The positions 
of reduced (red-AP), oxidized (ox-AP) and precursor (pre 
AP) are indicated. 
FIG. 4. Coexpression of rPDI improves the yield of BPTI 
as detected by FLISA. Bacterial cultures JCB570 containing 
pACYCBPTI (open bars) or pIPPsOmpArPDI and pACY 
CBPTI (solid bars) were induced with 0.1 mM IPTG at 
OD =0.3–0.35. GSH and/or GSSG as indicated was 
added 20 min after induction. Five hours after induction the 
cells were harvested and the concentration of BPTI in the 
soluble fraction was detected by ELISA. The data reported 
here represent the average of three independent Studies; for 
each Sample ELISAS were performed at least in triplicate. 
FIG. 5A. Western blot showing expression of BPTI with 
and without coexpression of rPDI. Bacterial cultures 
6,027,888 
17 
JCB570 (wild type), JCB571 (dsbA) and JCB789 (dsbB) 
carrying pACYCBPTI were induced (except those marked 
with a “U”) with 0.1 mM IPTG at ODoo =0.3–0.35. GSH 
and GSSG at the indicated mM concentrations were added 
20 min after induction. Five hours after induction the cells 
were harvested and the soluble fraction affinity precipitated 
with trypsin-agarose beads, electrophoresed through 16% 
SDS-PAGE Tricine gels and detected by Western blot. 
Shown are wild-type cells. Lane 1-2 soluble fraction of 
non-plasmid containing wild type cells with (X) and without 
(Y) an addition of 2 tug BPTI. 
FIG. 5B. Western blot showing expression of BPTI with 
and without coexpression of rPDI. Bacterial cultures 
JCB570 (wild type), JCB571 (dsbA) and JCB789 (dsbB) 
carrying pACYCBPTI were induced (except those marked 
with a “U”) with 0.1 mM IPTG at ODoo =0.3–0.35. GSH 
and GSSG at the indicated mM concentrations were added 
20 min after induction. Five hours after induction the cells 
were harvested and the soluble fraction affinity precipitated 
with trypsin-agarose beads, electrophoresed through 16% 
SDS-PAGE Tricine gels and detected by Western blot. 
Shown are Dsb mutant cells. Symbols: U=uninduced cells; 
pre-preOmpABPTI; #=degradation product of preOmp Ar 
PDI; rPDI-carrying plasmid pLPPsOmpArPDI. 
FIG. 6. Accumulation of two disulfide folding interme 
diates of BPTI in E. coli coexpressing rPDI as monitored by 
non-reducing electrophoresis. Proteins immunoprecipitated 
from cultures labeled with L-Scysteine for 1 min and 
quenched with 100 mM iodoacetamide were resolved on 
non-reducing gels containing 8 Murea. Times indicated are 
min after the chase. Lanes 1-4, no addition of glutathione. 
Lanes 5-8, 2 mM GSH added 30 min before pulse. The 
positions of preCompa-BPTI (Pre), reduced carboxymethy 
lated BPTI (R), native BPTI (N) and two disulfide interme 
diates (*) are indicated. 
FIG. 7. Restriction maps of the vectors pACYCBPTI and 
pTPA177. 
FIG.8. PhoA activity in R189 and R190 cells containing 
either no plasmid or pYPDI. 
4. DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
4.1 PROTEIN FOLDING IN VIVO 
Extensive Studies of the physicochemical aspects of the 
protein folding problem over the last 40 years have shed 
light on the nature of the rate limiting Steps during the 
formation of the native conformation. Rate limiting Steps in 
folding include non-covalent processes, Such as the align 
ment of protein Subdomains, Subunit assembly etc., and 
covalent processes, for example disulfide bond formation, 
peptidylproline isomerization, proprotein processing and 
others. In-Vivo, the rate of the covalent Steps is catalyzed by 
a host of cellular enzymes. On the other hand, partially 
folded species that accumulate because of slow conforma 
tional changes are protected from non-productive interac 
tions by the action of chaperones (Gething and Sambrook, 
1992). The reductionist approach of analyzing in vitro each 
of these StepS Separately has elucidated many mechanistic 
aspects of the folding problem. However, the folding of 
proteins in nature occurs in the concentrated milieu of the 
cellular environment and is probably coupled to biosynthesis 
and/or export. These additional factors together with the 
multitude of processes that affect folding in the first place, 
make it practically impossible to understand how folding 
proceeds in the cell Solely from in vitro data. 
The regulation of protein folding is essential for the 











environments. In addition, protein folding underlies the 
cause of many human disorders (Wetzel, 1994). A detailed 
analysis of the in Vivo folding pathway can shed light on the 
influence of various cellular parameters and the nature of 
rate limiting Steps in the folding of proteins in the cell. Such 
information will ultimately elucidate the molecular basis of 
this major biological mechanism and could have consider 
able medical implications. 
At present, the protein for which the most detailed infor 
mation on the kinetics and energetics of folding and on the 
structure of all the key intermediates is available, is BPTI. 
BPTI can be secreted to the periplasmic space of E. coli 
where it folds to the native state. Even though BPTI is a 
heterologous protein, it interacts with bacterial components 
and its folding is absolutely dependent on the function of E. 
coli oxidoreductases (Ostermeier and Georgiou, 1994). 
4.2 PROTEIN FOLDING IN VITRO 
The refolding of proteins from denaturant Solutions is a 
Spontaneous process directed by the amino acid Sequence 
and the solvent conditions (Matthews 1993; Fersht, 1993). 
However, even though folding is thermodynamically 
favored, the yield of the native protein upon refolding in 
vitro can range from almost 0 to 100%, and the time required 
for renaturation from milliseconds to days. The reason for 
Such differences relates to the kinetics of the folding process. 
Exciting recent Studies by Fersht and coworkers and others 
(Otzen et al., 1994; Kuszewski et al., 1994) suggest that the 
folding of protein Subdomains proceeds according to the 
global collapse model (Dillet al., 1993), via a transition state 
resembling an expanded form of the native conformation but 
with no fully formed elements of secondary or tertiary 
Structure. However, for more complex proteins other pro 
cesses Such as the alignment of Subdomains or covalent 
changes introduce rate limiting StepS. Covalent changes that 
limit folding include: cis-trans isomerization of peptidylpro 
line bonds, formation of disulfide bonds, proteolytic pro 
cessing of proproteins, heme ligation, etc. In the cell most, 
if not all of these rate limiting processes are facilitated by 
accessory proteins known as foldases and chaperones 
(Gething and Sambrook, 1992). Foldases have a clearly 
defined catalytic activity whereas chaperones perform mul 
tiple functions, the most important of which is providing an 
environment for nascent proteins to fold without the com 
peting process of Self-association. The distinction is Some 
what artificial because Some proteins like protein disulfide 
isomerase function both as foldases and chaperones, at least 
in vitro. 
The presence of accessory proteins underlies one of the 
fundamental differences between refolding Studies and the 
way in which folding proceeds in the cell. In addition, in 
Vitro Studies are conducted with highly purified polypeptides 
that are first unfolded and then allowed to relax to their 
native conformation in dilute Solutions. In contrast, the 
folding of proteins in the cell is probably coupled to protein 
Synthesis, takes place in a much more concentrated envi 
ronment and is affected by compartmentalization. To com 
plicate matters even more, the growth conditions affect 
folding directly, by influencing the rates of conformational 
and covalent changes, and indirectly, by modulating the 
expression and activity of accessory proteins. 
A central question in protein folding is to what extent in 
Vitro Studies reflect the physiological folding pathway. In the 
cell, newly Synthesized polypeptides can interact with a 
variety of chaperones and foldases and, quite possibly, with 
other cellular components Such as membranes, ligand or 
Substrate molecules, and low-molecular-weight Solutes. 
Furthermore, because of the vectorial nature of ribosomal 
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Synthesis, and of the export apparatus in the case of Secreted 
proteins, the initial State from which folding commences is 
non-random. 
The denatured State of the protein can exert a significant 
influence on the folding pathway. Unfortunately, determin 
ing the folding pathway in Vivo is not a Straightforward 
matter because of the paucity of methods for isolating 
partially folded proteins. ProgreSS in the elucidation of in 
Vivo folding processes has been possible only for proteins 
which form exceedingly stable intermediates, Such as the 
P22 endoramnosidase (Goldenberg and King, 1982; Mitraki 
et al., 1991) and for those where partially folded molecules 
can be trapped by blocking the formation of disulfide bonds. 
Studies by the groups of Helenius and Ruddon have 
employed chemical modification of free thiols to quench 
folding and dissect the pathway of disulfide bond formation 
in influenza he magglutin and human chorionic 
gonadotropin, respectively (Braakman et al., 1992, Bedows 
et al., 1992). However, only for the latter protein is the in 
vitro folding pathway sufficiently well characterized to 
allow a direct comparison with results of in Vivo Studies 
(Huth et al., 1993). Furthermore, the folding of H. influenza 
hemagglutin and human gonadotropin has been Studied in 
mammalian cells in which the use of genetic techniques for 
dissecting the role of cellular factors is technically difficult. 
The periplasmic space is the cellular compartment defined 
by the inner and Outer membranes of Gram-negative bacteria 
(Pugsley, 1993). Unlike the cytoplasm, the periplasmic 
Space is maintained under Strongly oxidizing conditions, 
thus facilitating the formation of disulfide bonds in secreted 
proteins (Walker and Gilbert, 1995; Wilfing and Pllickthun, 
1994). The majority of periplasmic proteins are exported 
across the cytoplasmic membrane via the general Secretion 
pathway (Pugsley, 1993) whose components include the 
proteins SecA, SecY, SecE, SecD, SecF and the recently 
discovered SecG (Nishiyama et al., 1994). Newly translo 
cated polypeptides are often transiently associated with the 
external face of the cytoplasmic membrane before they are 
released into the periplasm. There is evidence that this 
transient association with the membrane may be important 
for protein folding (Matsuyama et al., 1993). 
The bacterial periplasmic space is topologically equiva 
lent to the endoplasmic reticulum (ER) of eukaryotic cells 
and, just like in the ER, folding is modulated by the action 
of Several proteins. In addition, the periplasmic PapD chap 
erone is essential for the assembly of type I pili (Hultgren et 
al., 1993) and it has been proposed that CIpB may also 
function as a chaperone (Wilfing and Pluckthun, 1994). An 
important difference between periplasmic and cytoplasmic 
chaperones is that, unlike GroEL and DnaK, the binding and 
release of polypeptide Substrates from periplasmic chaper 
ones cannot involve ATPbinding/hydrolysis since there is no 
evidence for a high energy phosphate donor in the peri 
plasm. 
A protein with cis-trans proline isomerase activity 
(rotamase) has been isolated from E. coli periplasmic frac 
tions and has been shown to be active in a protein refolding 
assay (Wilfing and Pluckthun, 1994). However, the in vivo 
function of this protein has not yet been elucidated. 
The formation of disulfide bonds is catalyzed by the 
multicomponent dsb System. The dsb genes have been 
identified by genetic analysis. So far three proteins, DsbA, 
DsbB and DsbC have been characterized in Some detail 
(Bardwell, 1994, Shevchik et al., 1994, Missiakas et al., 
1994). Three additional genes that confer resistance to DTT 
have been isolated and named disbD, dsbE and disbF. Null 











formation of disulfide bonds in native proteins but little 
other information is currently available. 
4.3 BOVINE PANCREATIC TRYPSIN INHIBITOR 
One of the best characterized folding pathways in vitro is 
that of BPTI. The folding pathway has been elucidated 
through the isolation and characterization of the one- and 
two-disulfide intermediates that occur during folding 
(Creighton and Goldenberg, 1984, Weissman and Kim, 
1991; Goldenberg, 1992). The main steps in this pathway are 
shown below: 
Scheme 1 
--- I -s-s- I -d-e- 
N* 
R NSHSH -s - N 
where R is the fully reduced protein, I represents the various 
one-disulfide Species, II represents the native like interme 
diate N(30–51, 14-38) as well as two-disulfide species with 
one non-native and one native disulfide, N* represents the 
kinetic trap (5-55, 14–38), N' is the native-like species 
(3051, 5-55) and N is the native protein with three disul 
fides. The rate-limiting Step in folding is the conversion of 
II to N' which is then rapidly oxidized to the native 
protein. The Structure of all major doling intermediates has 
been extensively characterized using Hand 'N NMR (Van 
Mierlo et al., 1993). N*, and to a lesser extent N', have a 
native-like conformation and therefore the activation energy 
for the conformational change required to position the two 
thiols in close proximity is high and thus the rate of 
rearrangement to N' is slow. The unpaired cysteines of 
N* are buried within the interior of the protein. 
Consequently, N* is exceedingly slow to rearrange to other 
Species and is described as a kinetic trap in the folding 
pathway (Creighton and Goldenberg, 1984). 
4.4 EUKARYOTIC PDI 
PDI is an endoplasmic reticulum enzyme that catalyzes 
cysteine oxidation and disulfide bond rearrangement and is 
essential for cell viability in Saccharomyces cerevisiae 
(Freedman, 1989; Novia et al., 1991). In vitro, PDI has been 
shown to catalyze all steps in the BPTI folding pathway 
(Creighton et al., 1980) including the rearrangement of N' 
and N* to the labile intermediate N' under conditions 
that resemble those of the endoplasmic reticulum (Weissman 
and Kim, 1993). The folding of BPTI is accelerated by the 
presence of total protein from the endoplasmic reticulum, a 
phenomenon which has been shown to be totally accounted 
for by the activity of protein disulfide isomerase (Zapun et 
al., 1992). Creighton and co-workers (1993) studied the 
folding of proBPTI produced by an in vitro translation 
system and imported into microsomes. proBPTI consists of 
the mature protein with a 13-residue extension on the 
N-terminal and 7 residue extension at the C-terminal. Its 
folding was found to be dependent on the presence of GSSG. 
The formation of native protein was found to be substan 
tially higher than in vitro with complete folding occurring 
within I min under strongly oxidizing conditions (10 mM 
GSSG) and within 2 min with 4 mM GSSG. It was postu 
lated that the higher rate of folding in microSomes was due 
to PDI which was shown to catalyze both disulfide bond 
formation and rearrangement in proBPTI (Creighton et al., 
1993). 
The periplasmic space of E. coli is topologically equiva 
lent to the endoplasmic reticulum. It is maintained at a redox 
6,027,888 
21 
State favoring the formation of disulfide bonds, a proceSS 
which is accelerated by at least two interacting proteins, 
DsbA and DsbB (Bardwell and Beckwith, 1993; Bardwell et 
al., 1993). The three-dimensional structure of DsbA was 
Solved recently and shown to consist of a thioredoxin-like 
domain joined to a Second domain which may be responsible 
for substrate specificity (Martin et al., 1993). Similarly, PDI 
has also been predicted to contain thioredoxin-like domains. 
Given the analogies between the endoplasmic reticulum and 
the bacterial periplasmic space, it is not Surprising that 
native BPTI can form in E. coli provided it is expressed with 
a bacterial leader peptide (Marks et al., 1986; Goldenberg, 
1988). 
Eukaryotic PDI is a 55 kDa enzyme with cysteine 
oxidoreductase, chaperon and antichaperon activities that 
catalyzes disulfide formation and rearrangement in the 
eukaryotic endoplasmic reticulum. In Sharp contrast, in 
Gram-negative bacteria, the formation of disulfide bonds in 
the periplasm is mediated by DsbA, a strong cysteine 
oxidase but an inefficient catalyst of disulfide bond isomer 
ization with no known chaperon activity. 
The prokaryotic analog was utilized in Eur. Pat. Appl. No. 
EP 510,658 to direct the expression of a single disulfide 
bond-containing polypeptide, C.-amylase/trypsin inhibitor 
(RBI), but unfortunately the method required the addition of 
critical amounts of thiol reagents to the culture medium. The 
present inventors have shown, however, that the prokaryotic 
enzyme disclosed in Eur. Pat. Appl. No. EP 510,658 was 
unable to direct the Secretion of Significant quantities of 
either active tRA or active BPTI from bacterial host cells. 
Surprisingly, however, when the inventors genetically 
engineered recombinant host cells to contain a eukaryotic 
foldase, namely, a disulfide isomerase, the mammalian 
enzyme was not only Secreted into the periplasmic space of 
bacterial cells, but was also able to catalyze the formation of 
disulfide bonds, and complement Several dsbA mutants 
which lacked the bacterial enzyme. The function of rPDI 
was dependent on the disbB gene Suggesting that the reoxi 
dation of this eukaryotic enzyme involves direct interactions 
with bacterial redox proteins. 
Even more importantly, the inventors have demonstrated 
that co-expression of the eukaryotic rPDI increased the yield 
of eukaryotic proteins such as BPTI several fold. Whereas 
PDI is thought to function primarily as an isomerase in the 
eukaryotic endoplasmic reticulum, rPDI failed to decrease 
the accumulation of two disulfide folding intermediates of 
BPTI and thus did not appear to appreciably catalyze the rate 
limiting step in the oxidative folding pathway of BPTI. 
In a breakthrough for protein production in bacterial 
hosts, the present invention now provides novel methods 
and compositions to facilitate the expression of eukaryotic 
foldases in bacterial cells and provides new expression 
Systems which may now be exploited to increase the yield of 
biologically-valuable eukaryotic proteins which have not 
been previously been produced in prokaryotic hosts in 
biologically-active forms. 
4.5 METHODS OF NUCLEIC ACID DELIVERY AND DNATRANS 
FORMATION 
In yet another embodiment, the present invention pro 
vides recombinant host cells transformed with polynucle 
otides which encode an eukaryotic foldase, and particular 
disulfide bond-containing polypeptides of interest, as well as 
transgenic cells derived from those transformed or trans 
fected cells. Preferably, a recombinant host cell of the 
present invention is transformed with a polynucleotide com 
prising a Sequence encoding PDI and a polynucleotide 











transforming cells with exogenous polynucleotide Such as 
DNA molecules are well known in the art and include 
techniques Such as calcium-phosphate- or DEAE 
deXtranmediated transfection, protoplast fusion, 
electroporation, liposome mediated transfection, direct 
microinjection and adenovirus infection (Sambrook et al., 
1989). 
The application of brief, high-voltage electric pulses to a 
cell culture leads to the formation of nanometer-sized pores 
in the cell membrane. DNA is taken directly into the 
cytoplasm either through these pores or as a consequence of 
the redistribution of membrane components that accompa 
nies closure of the pores. Electroporation can be extremely 
efficient and can be used both for transient expression of 
cloned genes and for establishment of cell lines that carry 
integrated copies of the gene of interest. Electroporation, in 
contrast to calcium chloride-mediated transformation, fre 
quently gives rise to high numbers of target cells being 
transformed with the foreign DNA. 
Liposome transfection involves encapsulation of DNA 
and RNA within liposomes, followed by fusion of the 
liposomes with the cell membrane. The mechanism of how 
DNA is delivered into the cell is unclear but transfection 
efficiencies can be as high as 90%. 
4.6 DNA SEGMENTS 
In other embodiments, it is contemplated that certain 
advantages will be gained by positioning the DNA segment 
encoding the fusion polypeptides under the control of a 
recombinant, or heterologous, promoter. AS used herein, a 
recombinant or heterologous promoter is intended to refer to 
a promoter that is not normally associated with a DNA 
Segment encoding the eukaryotic peptide in its natural 
environment. Such promoters may include promoters nor 
mally associated with other genes, and/or promoters isolated 
from any viral, prokaryotic (e.g., bacterial), eukaryotic (e.g., 
fungal, yeast, plant, or animal) cell, and particularly those of 
mammalian cells. Naturally, it will be important to employ 
a promoter that effectively directs the expression of the DNA 
Segment in the cell type, organism, or even animal, chosen 
for expression. The use of promoter and cell type combina 
tions for protein expression is generally known to those of 
skill in the art of molecular biology, for example, See 
Sambrook et al., 1989. The promoters employed may be 
constitutive, or inducible, and can be used under the appro 
priate conditions to direct high level expression of the 
introduced DNA segment, Such as is advantageous in the 
large-scale production of recombinant proteins or peptides. 
Appropriate promoter/expression Systems contemplated for 
use in high-level expression include, but are not limited to, 
the Pichia expression vector system (Pharmacia LKB 
Biotechnology), a baculovirus System for expression in 
insect cells, or any Suitable yeast or bacterial expression 
System. 
The ability of nucleic acid Segments to be used as probes 
to specifically hybridize to the disclosed DNA sequences 
will enable them to be of use in detecting the presence of 
complementary Sequences in a given Sample. However, 
other uses are envisioned, including the use of the Sequence 
information for the preparation of mutant Species primers, or 
primers for use in preparing other genetic constructions. 
Nucleic acid molecules having Sequence regions consist 
ing of contiguous nucleotide Stretches of about 14, 15-20, 
30, 40, 50, or even of about 100 to about 200 nucleotides or 
So, identical or complementary to the DNA sequences dis 
closed herein, are particularly contemplated as hybridization 
probes for use in, e.g., Southern and Northern blotting. 
Smaller fragments will generally find use in hybridization 
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embodiments, wherein the length of the contiguous comple 
mentary region may be varied, Such as between about 10 and 
about 14 or even up to about 25, 50, or 100 nucleotides, but 
larger contiguous complementarity Stretches may be used, 
according to the length complementary Sequences one 
wishes to detect. 
The use of a hybridization probe of about 14 nucleotides 
in length allows the formation of a duplex molecule that is 
both Stable and Selective. Molecules having contiguous 
complementary Sequences over Stretches greater than 14 
bases in length are generally preferred, though, in order to 
increase stability and selectivity of the hybrid, and thereby 
improve the quality and degree of Specific hybrid molecules 
obtained. One will generally prefer to design nucleic acid 
molecules having gene-complementary Stretches of about 15 
to about 25 contiguous nucleotides, or even longer where 
desired. 
Of course, fragments may also be obtained by other 
techniques Such as, e.g., by mechanical shearing or by 
restriction enzyme digestion. Small nucleic acid Segments or 
fragments may be readily prepared by, for example, directly 
Synthesizing the fragment by chemical means, as is com 
monly practiced using an automated oligonucleotide Syn 
thesizer. Also, fragments may be obtained by application of 
nucleic acid reproduction technology, such as PCRTM 
(exemplified in U.S. Pat. Nos. 4,683.202 and 4,683,195), by 
introducing Selected Sequences into recombinant vectors for 
recombinant production, and by other recombinant DNA 
techniques generally known to those of skill in the art of 
molecular biology. 
Accordingly, the nucleotide Sequences of the invention 
may be used for their ability to selectively form duplex 
molecules with complementary stretches of DNA fragments. 
Depending on the application envisioned, one will desire to 
employ varying conditions of hybridization to achieve vary 
ing degrees of Selectivity of probe towards target Sequence. 
For applications requiring high Selectivity, one will typically 
desire to employ relatively Stringent conditions to form the 
hybrids, e.g., one will Select relatively low Salt and/or high 
temperature conditions, such as provided by about 0.02 M to 
about 0.15 M NaCl at temperatures of about 50° C. to about 
70° C. Such selective conditions tolerate little, if any, 
mismatch between the probe and the template or target 
Strand, and would be particularly Suitable for isolating 
MSCRAMM-encoding DNA segments. Detection of DNA 
Segments via hybridization is well-known to those of skill in 
the art, and the teachings of U.S. Pat. Nos. 4,965,188 and 
5,176,995 (each incorporated herein by reference) are exem 
plary of the methods of hybridization analyses. Teachings 
such as those found in the texts of Maloy, 1990; Maloy et al., 
1994; Segal, 1976; Prokop, 1991; and Kuby, 1994, are 
particularly relevant, providing detailed methods and pro 
tocols for molecular biology methods, hybridization and 
instruction enzyme digestion, plasmid construction, DNA 
and RNA sequencing mutant construction and analysis and 
other related methods. 
Of course, for Some applications, for example, where one 
desires to prepare mutants employing a mutant primer Strand 
hybridized to an underlying template or where one Seeks to 
isolate eukaryotic polypeptide-encoding Sequences from 
related Species, functional equivalents, or the like, leSS 
Stringent hybridization conditions will typically be needed in 
order to allow formation of the heteroduplex. In these 
circumstances, one may desire to employ conditions Such as 
about 0.15 M to about 0.9 M salt, at temperatures ranging 
from about 20° C. to about 55 C. Cross-hybridizing species 











Signals with respect to control hybridizations. In any case, it 
is generally appreciated that conditions can be rendered 
more Stringent by the addition of increasing amounts of 
formamide, which serves to destabilize the hybrid duplex in 
the same manner as increased temperature. Thus, hybrid 
ization conditions can be readily manipulated, and thus will 
generally be a method of choice depending on the desired 
results. 
In certain embodiments, it will be advantageous to 
employ nucleic acid Sequences of the present invention in 
combination with an appropriate means, Such as a label, for 
determining hybridization. A wide variety of appropriate 
indicator means are known in the art, including fluorescent, 
radioactive, enzymatic or other ligands, Such as avidin/ 
biotin, which are capable of giving a detectable signal. In 
preferred embodiments, one will likely desire to employ a 
fluorescent label or an enzyme tag, Such as urease, alkaline 
phosphatase or peroxidase, instead of radioactive or other 
environmental undesirable reagents. In the case of enzyme 
tags, colorimetric indicator Substrates are known that can be 
employed to provide a means visible to the human eye or 
Spectrophotometrically, to identify Specific hybridization 
with complementary nucleic acid-containing Samples. 
In general, it is envisioned that the hybridization probes 
described herein will be useful both as reagents in solution 
hybridization as well as in embodiments employing a Solid 
phase. In embodiments involving a Solid phase, the test 
DNA (or RNA) is adsorbed or otherwise affixed to a selected 
matrix or Surface. This fixed, single-Stranded nucleic acid is 
then subjected to specific hybridization with selected probes 
under desired conditions. The selected conditions will 
depend on the particular circumstances based on the par 
ticular criteria required (depending, for example, on the 
G+C content, type of target nucleic acid, Source of nucleic 
acid, size of hybridization probe, etc.). Following washing 
of the hybridized Surface So as to remove nonspecifically 
bound probe molecules, specific hybridization is detected, or 
even quantitated, by means of the label. 
4.7 EXPRESSION OF EUKARYOTIC DISULFIDE-BOND CONTAIN 
ING PROTEINS 
The present inventors contemplate cloning the recombi 
nant polypeptides identified herein, and in particular recom 
binant tBA and PTI polypeptides. A technique often 
employed by those skilled in the art of protein production 
today is to obtain a so-called “recombinant version of the 
protein, to express it in a recombinant cell and to obtain the 
protein from Such cells. These techniques are based upon the 
“cloning” of a DNA molecule encoding the protein from a 
DNA library, i.e., on obtaining a specific DNA molecule 
distinct from other portions of DNA. This can be achieved 
by, for example, cloning a cDNA molecule, or cloning a 
genomic-like DNA molecule. TechniqueS Such as these 
would also, of course, be appropriate for the production of 
a disulfide bond-containing polypeptide in accordance with 
the present invention. 
The first Step in Such cloning procedures is the Screening 
of an appropriate DNA library, Such as, in the present case, 
a rat, human, bovine, or other mammalian-derived library. 
The Screening procedure may be an expression Screening 
protocol employing antibodies directed against the protein, 
or activity assays. Alternatively, Screening may be based on 
the hybridization of oligonucleotide probes, designed from 
a consideration of portions of the amino acid Sequence of the 
protein, or from the DNA sequences of genes encoding 
related proteins. The operation of Such Screening protocols 
are well known to those of skill in the art and are described 
in detail in the Scientific literature, e.g., in Sambrook et al. 
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(1989) specifically incorporated herein by reference. 
Moreover, as the present invention encompasses the cloning 
of genomic Segments as well as cDNA molecules, it is 
contemplated that other Suitable methods known to those in 
the art, Such as, e.g., those described by Spoerel et al. (1987), 
may also be used in connection with cloning a disulfide 
bond-containing polypeptide, or alternatively an eukaryotic 
foldase to direct the folding and isomerization of disulfide 
bonds contained within Such polypeptides of interest. 
After identifying appropriate DNA molecules, they may 
be inserted into any one of the many vectors currently 
known in the art and transferred to a prokaryotic or eukary 
otic host cell where it will direct the expression and pro 
duction of the So-called recombinant version of the protein. 
This is also, of course, routinely practiced in the art and 
described in various publications, Such as, e.g., Sambrook et 
al. (1989). Such DNA segments may be contained on a 
Single plasmid vector, or alternatively, the foldase may be 
encoded by nucleic acid Sequences on one vector and the 
disulfide bond-containing polypeptide of interest may be 
present on a Second plasmid vector which is compatible for 
co-residence in a single host cell with the first plasmid vector 
comprising the foldase Sequence. The Selection of plasmid 
vectors is well-known to those of skill in the art, and Such 
a Selection may be based on the incompatibility grouping of 
Such vectors (IncP, IncO, etc.). Virtually any Such plasmid 
vectors may be used in the practice of the invention So long 
as they are replicable in the appropriate prokaryotic host cell 
employed. In one embodiment, preferred replicons include 
pACYC184 and pTI 103, and in particular, the pACYCBPTI 
and pLPPs Omp ArPDI plasmid constructs derived 
respectively, therefrom. 
It will be understood that recombinant disulfide bond 
containing polypeptides may differ from naturally-produced 
polypeptides in certain ways. In particular, the degree of 
post-translational modifications, Such as, for example, gly 
cosylation and phosphorylation may be different between 
the recombinant and natural forms. 
Recombinant clones expressing nucleic acid Segments 
which encode eukaryotic disulfide-bond containing 
polypeptides may be used to prepare purified recombinant 
polypeptides, purified polypeptide-derived antigens as well 
as mutant or variant recombinant protein Species in Signifi 
cant quantities. In particular, the invention provides for the 
production of recombinant tFA (rtPA) or recombinant PTI 
(rPTI) in Substantial quantities from bacterial host cells. 
Additionally, by application of techniques Such as DNA 
mutagenesis, the present invention allows the ready prepa 
ration of So-called “Second generation' molecules having 
modified or Simplified protein Structures. Second generation 
proteins will typically share one or more properties in 
common with the full-length polypeptides, Such as a par 
ticular antigenic/immunogenic epitopic core Sequences, or 
particular catalytic Sites, active Sites, or ligand binding 
domains, etc. Epitopic Sequences can be provided on rela 
tively short molecules prepared from knowledge of the 
peptide, or encoding DNA sequence information. Such 
variant molecules may not only be derived from Selected 
immunogenic/antigenic regions of the protein Structure, but 
may additionally, or alternatively, include one or more 
functionally equivalent amino acids Selected on the basis of 
Similarities or even differences with respect to the natural 
Sequence. This is particularly desirable in the preparation of 
recombinant polypeptides having enhanced or Superior 
Stability, activity, binding, or affinity for Substrates and the 
like. 
The general process of recombinant expression of pro 











hosts, is well-known to those of skill in the art. It is generally 
preferred for the methods described herein that the DNA 
Sequence encoding the particular eukaryotic protein of inter 
est to be secreted be operatively linked to a DNA sequence 
which encodes a Signal peptide Sufficient for the transloca 
tion of the recombinant polypeptide to the periplasmic space 
of the bacterial host cell. AS it is well-known, operative links 
between Such DNA sequences mean that a translational 
fusion exists between the heterologous protein and the Signal 
peptide. As a rule, Such signal peptides form the N-terminal 
portion of the Secreted heterologous protein. Signal 
Sequences which promote protein translocation to the peri 
plasmic Space of Gram-negative bacterial are well-known, 
as exemplified by those described herein. The E. coli Omp A, 
Lpp, LamB, MalE, PelB, and StI leader peptide sequences 
have been Successfully used in many applications as Signal 
Sequences to promote protein Secretion in bacterial cells 
Such as those used herein, and are all contemplated to be 
useful in the practice of the invention. 
4.8 PROMOTERS, ENHANCERS, AND SIGNAL SEQUENCE ELE 
MENTS 
The promoters and enhancers that control the transcrip 
tion of protein-encoding genes are composed of multiple 
genetic elements. The cellular machinery is able to gather 
and integrate the regulatory information conveyed by each 
element, allowing different genes to evolve distinct, often 
complex patterns of transcriptional regulation. 
The term promoter will be used here to refer to a group of 
transcriptional control modules that are clustered around the 
initiation site for RNA polymerase II. Much of the thinking 
about how promoters are organized derives from analyses of 
several viral promoters, including those for the HSV thy 
midine kinase (tk) and SV40 early transcription units. These 
Studies, augmented by more recent work, have shown that 
promoters are composed of discrete functional modules, 
each consisting of approximately 7-20 bp of DNA, and 
containing one or more recognition Sites for transcriptional 
activator proteins. At least one module in each promoter 
functions to position the start site for RNA synthesis. The 
best known example of this is the TATA box, but in some 
promoters lacking a TATA box, Such as the promoter for the 
mammalian terminal deoxynucleotidyl transferase gene and 
the promoter for the SV 40 late genes, a discrete element 
overlying the Start Site itself helps to fix the place of 
initiation. 
Additional promoter elements regulate the frequency of 
transcriptional initiation. Typically, these are located in the 
region 30-110 bp upstream of the Start Site, although a 
number of promoters have recently been shown to contain 
functional elements downstream of the start site as well. The 
spacing between elements is flexible, So that promoter 
function is preserved when elements are inverted or moved 
relative to one another. In the tk promoter, the spacing 
between elements can be increased to 50 bp apart before 
activity begins to decline. Depending on the promoter, it 
appears that individual elements can function either coop 
eratively or independently to activate transcription. 
Enhancers were originally detected as genetic elements 
that increased transcription from a promoter located at a 
distant position on the same molecule of DNA. This ability 
to act over a large distance had little precedent in classic 
Studies of prokaryotic transcriptional regulation. 
Subsequent work showed that regions of DNA with 
enhancer activity are organized much like promoters. That 
is, they are composed of many individual elements, each of 
which binds to one or more transcriptional proteins. 
The basic distinction between enhancers and promoters is 
operational. An enhancer region as a whole must be able to 
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Stimulate transcription at a distance; this need not be true of 
a promoter region or its component elements. On the other 
hand, a promoter must have one or more elements that direct 
initiation of RNA synthesis at a particular site and in a 
particular orientation, whereas enhancers lack these speci 
ficities. Aside from this operational distinction, enhancers 
and promoters are very Similar entities. They have the same 
general function of activating transcription in the cell. They 
are often overlapping and contiguous, often Seeming to have 
a very similar modular organization. Taken together, these 
considerations Suggest that enhancers and promoters are 
homologous entities and that the transcriptional activator 
proteins bound to these Sequences may interact with the 
cellular transcriptional machinery in fundamentally the 
Same way. 
Particularly preferred promoters include the lac-lpp pro 
moter which is well-known in the art. Other promoters 
contemplated to be useful in the practice of the invention 
include the ara, lac, tac, tre, trp, phoA, PA, up, lpp, and 
the T7 promoter. 
4.9 SITE-SPECIFIC MUTAGENESIS 
Site-specific mutagenesis is a technique useful in the 
preparation of individual peptides, or biologically functional 
equivalent proteins or peptides, through Specific mutagen 
esis of the underlying DNA. The technique, well-known to 
those of skill in the art, further provides a ready ability to 
prepare and test Sequence variants, for example, incorporat 
ing one or more of the foregoing considerations, by intro 
ducing one or more nucleotide Sequence changes into the 
DNA. Site-specific mutagenesis allows the production of 
mutants through the use of Specific oligonucleotide 
Sequences which encode the DNA sequence of the desired 
mutation, as well as a Sufficient number of adjacent 
nucleotides, to provide a primer Sequence of Sufficient size 
and Sequence complexity to form a Stable duplex on both 
Sides of the deletion junction being traversed. Typically, a 
primer of about 14 to about 25 nucleotides in length is 
preferred, with about 5 to about 10 residues on both sides of 
the junction of the Sequence being altered. 
In general, the technique of Site-specific mutagenesis is 
well known in the art, as exemplified by various publica 
tions. AS will be appreciated, the technique typically 
employs a phage vector which exists in both a single 
stranded and double stranded form. Typical vectors useful in 
Site-directed mutagenesis include vectorS Such as the M13 
phage. These phage are readily commercially-available and 
their use is generally well-known to those skilled in the art. 
Double-Stranded plasmids are also routinely employed in 
Site directed mutagenesis which eliminates the Step of trans 
ferring the gene of interest from a plasmid to a phage. 
In general, Site-directed mutagenesis in accordance here 
with is performed by first obtaining a single-Stranded vector 
or melting apart of two Strands of a double-Stranded vector 
which includes within its Sequence a DNA sequence which 
encodes the desired peptide. An oligonucleotide primer 
bearing the desired mutated Sequence is prepared, generally 
Synthetically. This primer is then annealed with the Single 
Stranded vector, and Subjected to DNA polymerizing 
enzymes Such as E. coli polymerase I Klenow fragment, in 
order to complete the Synthesis of the mutation-bearing 
Strand. Thus, a heterodupleX is formed wherein one Strand 
encodes the original non-mutated Sequence and the Second 
strand bears the desired mutation. This heteroduplex vector 
is then used to transform appropriate cells, Such as E. coli 
cells, and clones are Selected which include recombinant 
vectors bearing the mutated Sequence arrangement. 
The preparation of Sequence variants of the Selected 











mutagenesis is provided as a means of producing potentially 
useful species and is not meant to be limiting as there are 
other ways in which Sequence variants of peptides and the 
DNA sequences encoding them may be obtained. For 
example, recombinant vectors encoding the desired peptide 
Sequence may be treated with mutagenic agents, Such as 
hydroxylamine, to obtain Sequence variants. Specific details 
regarding these methods and protocols are found in the 
teachings of Maloy (1990); Maloy et al. (1994); Segal 
(1976); Prokop and Bajpai (1991); Maniatis et al. (1982); 
and Sambrook et al. (1989), each incorporated herein by 
reference, for that purpose. 
The PCRTM-based strand overlap extension (SOE) for 
Site-directed mutagenesis is particularly preferred for Site 
directed mutagenesis of the nucleic acid compositions of the 
present invention. The techniques of PCRTM are well-known 
to those of skill in the art, as described hereinabove. The 
SOE procedure involves a two-step PCRTM protocol, in 
which a complementary pair of internal primers (B and C) 
are used to introduce the appropriate nucleotide changes into 
the wild-type Sequence. In two separate reactions, flanking 
PCRTM primer A (restriction site incorporated into the oligo) 
and primer D (restriction site incorporated into the oligo) are 
used in conjunction with primers B and C, respectively to 
generate PCRTM products AB and CD. The PCRTM products 
are purified by agarose gel electrophoresis and the two 
overlapping PCRTM fragments AB and CD are combined 
with flanking primers A and D and used in a second PCRTM 
reaction. The amplified PCRTM product is agarose gel 
purified, digested with the appropriate enzymes, ligated into 
an expression vector, and transformed into E. coli JM101, 
XL1-BLUETM (Stratagene, La Jolla, Calif.), JM105, TG1 
(Carter et al., 1985), or other Such Suitable cells as deemed 
appropriate depending upon the particular application of the 
invention. Clones are isolated and the mutations are con 
firmed by Sequencing of the isolated plasmids. Beginning 
with the native gene Sequences, for example, the nucleic 
acid Sequences encoding eukaryotic disulfide-bond 
containing polypeptides Such as PTI or tRA and the like, 
Suitable clones and Subclones may be made in the appro 
priate vectors from which Site-specific mutagenesis may be 
performed. 
4.10 BIOLOGICAL FUNCTIONALEOUIVALENTS 
Modification and changes may be made in the Structure of 
the peptides of the present invention and DNA segments 
which encode them and Still obtain a functional molecule 
that encodes a protein or peptide with desirable character 
istics. The following is a discussion based upon changing the 
amino acids of a protein to create an equivalent, or even an 
improved, Second-generation molecule. The amino acid 
changes may be achieved by changing the codons of the 
DNA sequence, according to Table 1. 
TABLE 1. 
Amino Acids Codons 
Alanine Ala A GCA GCC GCG GCU 
Cysteine Cys C UGU UGU 
Aspartic acid Asp D GAC GAU 
Glutamic acid Glu E GAA GAG 
Phenylalanine Phe F UUC UUU 
Glycine Gly G GGA GGC GGG GGU 
Histidine His H CAC CAU 
Isoleucine Ile I AUA AUC AUU 
Lysine Lys K AAA AAG 
Leucine Leu L UUA UUG CUA CUC CUG CUU 
Methionine Met M AUG 




Amino Acids Codons 
Proline Pro P CCA CCC CCG CCU 
Glutamine Glin O CAA CAG 
Arginine Arg R AGA AGG CGA CGC CGG CGU 
Serine Ser S AGC AGU UCA UCC UCG UCU 
Threonine Thir T ACA ACC ACG ACU 
Valine Val V GUA GUC GUC GUU 
Tryptophan Trp W UGG 
Tyrosin Tyr Y UAC UAU 
For example, certain amino acids may be Substituted for 
other amino acids in a protein Structure without appreciable 
loSS of interactive binding capacity with Structures Such as, 
for example, antigen-binding regions of antibodies or bind 
ing Sites on Substrate molecules. Since it is the interactive 
capacity and nature of a protein that defines that protein's 
biological functional activity, certain amino acid Sequence 
Substitutions can be made in a protein Sequence, and, of 
course, its underlying DNA coding Sequence, and neverthe 
less obtain a protein with like properties. It is thus contem 
plated by the inventors that various changes may be made in 
the peptide Sequences of the disclosed compositions, or 
corresponding DNA sequences which encode Said peptides 
without appreciable loSS of their biological utility or activity. 
In making Such changes, the hydropathic index of amino 
acids may be considered. The importance of the hydropathic 
amino acid indeX in conferring interactive biologic function 
on a protein is generally understood in the art (Kyte and 
Doolittle, 1982, incorporate herein by reference). It is 
accepted that the relative hydropathic character of the amino 
acid contributes to the Secondary Structure of the resultant 
protein, which in turn defines the interaction of the protein 
with other molecules, for example, enzymes, Substrates, 
receptors, DNA, antibodies, antigens, and the like. Each 
amino acid has been assigned a hydropathic indeX on the 
basis of their hydrophobicity and charge characteristics 
(Kyte and Doolittle, 1982), these are: isoleucine (+4.5); 
valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/ 
cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine 
(-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); 
tyrosine (-1.3), proline (-1.6); histidine (-3.2); glutamate 
(-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); 
lysine (-3.9); and arginine (-4.5). 
It is known in the art that certain amino acids may be 
Substituted by other amino acids having a similar hydro 
pathic index or Score and Still result in a protein with Similar 
biological activity, i.e., Still obtain a biological functionally 
equivalent protein. In making Such changes, the Substitution 
of amino acids whose hydropathic indices are within t2 is 
preferred, those which are within t1 are particularly 
preferred, and those within t0.5 are even more particularly 
preferred. It is also understood in the art that the substitution 
of like amino acids can be made effectively on the basis of 
hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein 
by reference, States that the greatest local average hydro 
philicity of a protein, as governed by the hydrophilicity of its 
adjacent amino acids, correlates with a biological property 
of the protein. 
As detailed in U.S. Pat. No. 4,554,101, the following 
hydrophilicity values have been assigned to amino acid 
residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 t1); 
glutamate (+3.0 t1); Serine (+0.3); asparagine (+0.2); 
glutamine (+0.2); glycine (O); threonine (-0.4); proline 
(-0.5 +1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); 











(-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan 
(-3.4). It is understood that an amino acid can be Substituted 
for another having a similar hydrophilicity value and Still 
obtain a biologically equivalent, and in particular, an immu 
nologically equivalent protein. In Such changes, the Substi 
tution of amino acids whose hydrophilicity values are within 
t2 is preferred, those which are within t1 are particularly 
preferred, and those within t0.5 are even more particularly 
preferred. 
AS outlined above, amino acid Substitutions are generally 
therefore based on the relative similarity of the amino acid 
Side-chain Substituents, for example, their hydrophobicity, 
hydrophilicity, charge, size, and the like. Exemplary Substi 
tutions which take various of the foregoing characteristics 
into consideration are well known to those of skill in the art 
and include: arginine and lysine; glutamate and aspartate; 
Serine and threonine; glutamine and asparagine; and Valine, 
leucine and isoleucine. 
4.11 PHARMACEUTICAL COMPOSITIONS 
In certain embodiments, the inventors contemplate the 
formulation of the eukaryotic polypeptides produced in 
bacteria using the methods disclosed herein into 
pharmaceutically-acceptable compositions for administra 
tion to an animal, and in particular, a mammal Such as a 
human. 
Such pharmaceutical compositions may be orally 
administered, for example, with an inert diluent or with an 
assimilable edible carrier, or they may be enclosed in hard 
or Soft shell gelatin capsule, or they may be compressed into 
tablets, or they may be incorporated directly with the food 
of the diet. For oral therapeutic administration, the active 
compounds may be incorporated with excipients and used in 
the form of ingestible tablets, buccal tables, troches, 
capsules, elixirs, Suspensions, Syrups, wafers, and the like. 
Such compositions and preparations should contain at least 
0.1% of active compound. The percentage of the composi 
tions and preparations may, of course, be varied and may 
conveniently be between about 2 to about 60% of the weight 
of the unit. The amount of active compounds in Such 
therapeutically useful compositions is Such that a Suitable 
dosage will be obtained. 
The tablets, troches, pills, capsules and the like may also 
contain the following: a binder, as gum tragacanth, acacia, 
cornstarch, or gelatin; excipients, Such as dicalcium phos 
phate, a disintegrating agent, Such as corn Starch, potato 
Starch, alginic acid and the like; a lubricant, Such as mag 
nesium Stearate; and a Sweetening agent, Such as Sucrose, 
lactose or Saccharin may be added or a flavoring agent, Such 
as peppermint, oil of wintergreen, or cherry flavoring. When 
the dosage unit form is a capsule, it may contain, in addition 
to materials of the above type, a liquid carrier. Various other 
materials may be present as coatings or to otherwise modify 
the physical form of the dosage unit. For instance, tablets, 
pills, or capsules may be coated with shellac, Sugar or both. 
A Syrup of elixir may contain the active compounds Sucrose 
as a Sweetening agent methyl and propylparabens as 
preservatives, a dye and flavoring, Such as cherry or orange 
flavor. Of course, any material used in preparing any dosage 
unit form should be pharmaceutically pure and Substantially 
non-toxic in the amounts employed. In addition, the active 
compounds may be incorporated into Sustained-release 
preparation and formulations. 
The active compounds may also be administered parenter 
ally or intraperitoneally. Solutions of the active compounds 
as free base or pharmacologically acceptable Salts can be 
prepared in water Suitably mixed with a Surfactant, Such as 
hydroxypropylcellulose. Dispersions can also be prepared in 
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glycerol, liquid polyethylene glycols, and mixtures thereof 
and in oils. Under ordinary conditions of Storage and use, 
these preparations contain a preservative to prevent the 
growth of microorganisms. 
The pharmaceutical forms Suitable for injectable use 
include Sterile aqueous Solutions or dispersions and Sterile 
powders for the extemporaneous preparation of Sterile 
injectable Solutions or dispersions. In all cases the form must 
be Sterile and must be fluid to the extent that easy Syring 
ability exists. It must be stable under the conditions of 
manufacture and Storage and must be preserved against the 
contaminating action of microorganisms, Such as bacteria 
and fungi. The carrier can be a Solvent or dispersion medium 
containing, for example, water, ethanol, polyol (for example, 
glycerol, propylene glycol, and liquid polyethylene glycol, 
and the like), Suitable mixtures thereof, and vegetable oils. 
The proper fluidity can be maintained, for example, by the 
use of a coating, Such as lecithin, by the maintenance of the 
required particle size in the case of dispersion and by the use 
of Surfactants. The prevention of the action of microorgan 
isms can be brought about by various antibacterial and 
antifungal agents, for example, parabens, chlorobutanol, 
phenol, Sorbic acid, thimerosal, and the like. In many cases, 
it will be preferable to include isotonic agents, for example, 
SugarS or Sodium chloride. Prolonged absorption of the 
injectable compositions can be brought about by the use in 
the compositions of agents delaying absorption, for 
example, aluminum monoStearate and gelatin. 
Sterile injectable Solutions are prepared by incorporating 
the active compounds in the required amount in the appro 
priate Solvent with various of the other ingredients enumer 
ated above, as required, followed by filtered Sterilization. 
Generally, dispersions are prepared by incorporating the 
various Sterilized active ingredients into a Sterile vehicle 
which contains the basic dispersion medium and the 
required other ingredients from those enumerated above. In 
the case of Sterile powders for the preparation of Sterile 
injectable Solutions, the preferred methods of preparation 
are vacuum-drying and freeze-drying techniques which 
yield a powder of the active ingredient plus any additional 
desired ingredient from a previously Sterile-filtered Solution 
thereof. 
AS used herein, "pharmaceutically acceptable carrier' 
includes any and all Solvents, dispersion media, coatings, 
antibacterial and antifungal agents, isotonic and absorption 
delaying agents and the like. The use of Such media and 
agents for pharmaceutical active Substances is well known in 
the art. Except insofar as any conventional media or agent is 
incompatible with the active ingredient, its use in the thera 
peutic compositions is contemplated. Supplementary active 
ingredients can also be incorporated into the compositions. 
For oral prophylaxis the polypeptide may be incorporated 
with excipients and used in the form of non-ingestible 
mouthwashes and dentifrices. A mouthwash may be pre 
pared incorporating the active ingredient in the required 
amount in an appropriate Solvent, Such as a Sodium borate 
solution (Dobell's Solution). Alternatively, the active ingre 
dient may be incorporated into an antiseptic wash containing 
Sodium borate, glycerin and potassium bicarbonate. The 
active ingredient may also be dispersed in dentifrices, 
including: gels, pastes, powders and Slurries. The active 
ingredient may be added in a therapeutically effective 
amount to a paste dentifrice that may include water, binders, 
abrasives, flavoring agents, foaming agents, and humectants. 
The phrase “pharmaceutically-acceptable” refers to 
molecular entities and compositions that do not produce an 











a human. The preparation of an aqueous composition that 
contains a protein as an active ingredient is well understood 
in the art. Typically, Such compositions are prepared as 
injectables, either as liquid Solutions or Suspensions, Solid 
forms Suitable for Solution in, or Suspension in, liquid prior 
to injection can also be prepared. The preparation can also 
be emulsified. 
The composition can be formulated in a neutral or Salt 
form. Pharmaceutically-acceptable Salts, include the acid 
addition Salts (formed with the free amino groups of the 
protein) and which are formed with inorganic acids Such as, 
for example, hydrochloric or phosphoric acids, or Such 
organic acids as acetic, oxalic, tartaric, mandelic, and the 
like. Salts formed with the free carboxyl groups can also be 
derived from inorganic baseS Such as, for example, Sodium, 
potassium, ammonium, calcium, or ferric hydroxides, and 
Such organic bases as isopropylamine, trimethylamine, 
histidine, procaine and the like. Upon formulation, Solutions 
will be administered in a manner compatible with the dosage 
formulation and in Such amount as is therapeutically effec 
tive. The formulations are easily administered in a variety of 
dosage forms Such as injectable Solutions, drug release 
capsules and the like. 
For parenteral administration in an aqueous Solution, for 
example, the solution should be suitably buffered if neces 
Sary and the liquid diluent first rendered isotonic with 
Sufficient Saline or glucose. These particular aqueous Solu 
tions are especially Suitable for intravenous, intramuscular, 
Subcutaneous and intraperitoneal administration. In this 
connection, Sterile aqueous media which can be employed 
will be known to those of skill in the art in light of the 
present disclosure. For example, one dosage could be dis 
Solved in 1 ml of isotonic NaCl Solution and either added to 
1000 ml of hypodermoclysis fluid or injected at the proposed 
Site of infusion, (see for example, “Remington's Pharma 
ceutical Sciences' 15th Edition, pages 1035-1038 and 
1570–1580). Some variation in dosage will necessarily 
occur depending on the condition of the Subject being 
treated. The perSon responsible for administration will, in 
any event, determine the appropriate dose for the individual 
Subject. Moreover, for human administration, preparations 
should meet Sterility, pyrogenicity, general Safety and purity 
standards as required by FDA Office of Biologics standards. 
4.12 LIPOSOMES AND NANOCAPSULES 
In certain aspects, it may be desirable to formulate the 
novel fusion proteins of the present invention into formu 
lations for administration to an animal or other organism. 
The administration of the compositions disclosed herein 
may be accomplished with pharmaceutical formulations of 
these eukaryotic polypeptides in the form of liposomes or 
nanocapsules for either general administration or for Specific 
targeting to certain areas, cells, or tissueS of an animal. 
The formation and use of liposomes is generally known to 
those of skill in the art (see e.g., Couvreur et al., 1977; 1988, 
which describe the use of liposomes and nanocapsules in the 
targeted antibiotic therapy of intracellular bacterial infec 
tions and diseases). Recently, liposomes were developed 
with improved serum stability and circulation half-times 
(Gabizon and Papahadjopoulos, 1988; Allen and Choun, 
1987). 
Liposomes have been used Successfully with a number of 
cell types that are normally resistant to transfection by other 
procedures including T cell Suspensions, primary hepatocyte 
cultures and PC 12 cells (Muller el al., 1990). In addition, 
liposomes are free of the DNA length constraints that are 
typical of Viral-based delivery Systems. Liposomes have 
been used effectively to introduce genes, drugs (Heath and 
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Martin, 1986; Heath et al., 1986; Balazsovits et al., 1989), 
radiotherapeutic agents (Pikul et al., 1987), enzymes 
(Imaizumi et al., 1990a, Imaizumi et al., 1990b), viruses 
(Faller and Baltimore, 1984), transcription factors and allos 
teric effectors (Nicolau and Gersonde, 1979) into a variety 
of cultured cell lines and animals. 
In addition to the teachings of Couvreur et al. (1977; 
1988), the following information may be utilized in gener 
ating liposomal formulations. Phospholipids can form a 
variety of Structures other than liposomes when dispersed in 
water, depending on the molar ratio of lipid to water. At low 
ratios the liposome is the preferred Structure. The physical 
characteristics of liposomes depend on pH, ionic Strength 
and the presence of divalent cations. Liposomes can Show 
low permeability to ionic and polar Substances, but at 
elevated temperatures undergo a phase transition which 
markedly alters their permeability. The phase transition 
involves a change from a closely packed, ordered Structure, 
known as the gel State, to a loosely packed, leSS-ordered 
Structure, known as the fluid State. This occurs at a charac 
teristic phase-transition temperature and results in an 
increase in permeability to ions, Sugars and drugs. 
In addition to temperature, exposure to proteins can alter 
the permeability of liposomes. Certain Soluble proteins Such 
as cytochrome c bind, deform and penetrate the bilayer, 
thereby causing changes in permeability. Cholesterol inhib 
its this penetration of proteins, apparently by packing the 
phospholipids more tightly. It is contemplated that the most 
useful liposome formations for antibiotic and inhibitor deliv 
ery will contain cholesterol. 
Targeting is generally not a limitation in terms of the 
present invention. However, should specific targeting be 
desired, methods are available for this to be accomplished. 
Antibodies may be used to bind to the liposome Surface and 
to direct the antibody and its drug contents to specific 
antigenic receptors located on a particular cell-type Surface. 
Carbohydrate determinants (glycoprotein or glycolipid cell 
Surface components that play a role in cell-cell recognition, 
interaction and adhesion) may also be used as recognition 
Sites as they have potential in directing liposomes to par 
ticular cell types. Mostly, it is contemplated that intravenous 
injection of liposomal preparations would be used, but other 
routes of administration are also conceivable. 
Alternatively, the invention provides for 
phannaceutically-acceptable nanocapsule formulations of 
dopamine receptor agonists. Nanocapsules can generally 
entrap compounds in a stable and reproducible way (Henry 
Michelland et al., 1987). To avoid side effects due to 
intracellular polymeric Overloading, Such ultrafine particles 
(sized around 0.1:m) should be designed using polymers 
able to be degraded in vivo. Biodegradable polyalkyl 
cyanoacrylate nanoparticles that meet these requirements 
are contemplated for use in the present invention, and Such 
particles may be are easily made, as described (Couvreur et 
al., 1984; 1988). 
4.13 ANTIBODY COMPOSITIONS 
In another aspect, the present invention contemplates an 
antibody that is immunoreactive with one of the recombi 
nant eukaryotic polypeptides obtained by the disclosed 
methods of producing Such fusion peptides in a bacterial 
host. Reference to antibodies throughout the Specification 
includes whole polyclonal and monoclonal antibodies, and 
parts thereof, either alone or conjugated with other moieties. 
Antibody parts include Fab and F(ab) fragments and single 
chain antibodies. The antibodies may be made in vivo in 
Suitable laboratory animals or in vitro using recombinant 











monoclonal antibody. In a preferred embodiment, an anti 
body is a polyclonal antibody. 
Means for preparing and characterizing antibodies are 
well known in the art (See, e.g., Harlow and Lane, 1988). 
Briefly, a polyclonal antibody is prepared by immunizing an 
animal with an immunogen comprising a polypeptide of the 
present invention and collecting antisera from that immu 
nized animal. A wide range of animal Species can be used for 
the production of antisera. Typically an animal used for 
production of anti-antisera is a rabbit, a mouse, a rat, a 
hamster or a guinea pig. Because of the relatively large 
blood volume of rabbits, a rabbit is a preferred choice for 
production of polyclonal antibodies. 
AS is well known in the art, a given composition may vary 
in its immunogenicity. It is often necessary therefore to 
boost the host immune System, as may be achieved by 
coupling a peptide or polypeptide immunogen to a carrier. 
Exemplary and preferred carriers are keyhole limpet 
hemocyanin (KLH) and bovine serum albumin (BSA). 
Other albumins Such as ovalbumin, mouse Serum albumin or 
rabbit Serum albumin can also be used as carriers. Means for 
conjugating a polypeptide to a carrier protein are well 
known in the art and include glutaraldehyde, 
m-maleimidobencoyl-N-hydroxySuccinimide ester, carbodi 
imide and bis-biazotized benzidine. 
AS is also well known in the art, the immunogenicity of 
a particular immunogen composition can be enhanced by the 
use of non-specific Stimulators of the immune response, 
known as adjuvants. Exemplary and preferred adjuvants 
include complete Frcunds adjuvant (a non-specific stimu 
lator of the immune response containing killed Mycobacte 
rium tuberculosis), incomplete Freund's adjuvants and alu 
minum hydroxide adjuvant. 
mAbs may be readily prepared through use of well-known 
techniques, such as those exemplified in U.S. Pat. No. 
4,196,265, incorporated herein by reference. Typically, this 
technique involves immunizing a Suitable animal with a 
Selected immunogen composition, e.g., a purified or partially 
purified protein, polypeptide or peptide. The immunizing 
composition is administered in a manner effective to Stimu 
late antibody producing cells. Rodents Such as mice and rats 
are preferred animals, however, the use of rabbit, sheep frog 
cells is also possible. The use of rats may provide certain 
advantages (Goding, 1986), but mice are preferred, with the 
BALB/c mouse being most preferred as this is most rou 
tinely used and generally gives a higher percentage of Stable 
fusions. 
Following immunization, Somatic cells with the potential 
for producing antibodies, Specifically B-lymphocytes 
(B-cells), are selected for use in the mab generating proto 
col. These cells may be obtained from biopsied Spleens, 
tonsils or lymph nodes, or from a peripheral blood Sample. 
Spleen cells and peripheral blood cells are preferred, the 
former because they are a rich Source of antibody-producing 
cells that are in the dividing plasmablast Stage, and the latter 
because peripheral blood is easily accessible. Often, a panel 
of animals will have been immunized and the Spleen of 
animal with the highest antibody titer will be removed and 
the Spleen lymphocytes obtained by homogenizing the 
Spleen with a Syringe. Typically, a spleen from an immu 
nized mouse contains approximately about 5x107 to about 
2x10 lymphocytes. 
The antibody-producing B lymphocytes from the immu 
nized animal are then fused with cells of an immortal 
myeloma cell, generally one of the same Species as the 
animal that was immunized. Myeloma cell lines Suited for 
use in hybridoma-producing fusion procedures preferably 
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are non-antibody-producing, have high fusion efficiency, 
and enzyme deficiencies that render then incapable of grow 
ing in certain Selective media which Support the growth of 
only the desired fused cells (hybridomas). 
Any one of a number of myeloma cells may be used, as 
are known to those of skill in the art (Goding, 1986; 
Campbell, 1984). One preferred murine myeloma cell is the 
NS-1 myeloma cell line (also termed P3-NS-1-Ag4-1), 
which is readily available from the NIGMS Human Genetic 
Mutant Cell Repository by requesting cell line repository 
number GM3573. Another mouse myeloma cell line that 
may be used is the 8-azaguanine-resistant mouse murine 
myeloma SP2/0 non-producer cell line. 
Methods for generating hybrids of antibody-producing 
Spleen or lymph node cells and myeloma cells usually 
comprise mixing Somatic cells with myeloma cells in a 2:1 
ratio, though the ratio may vary from about 20:1 to about 
1:1, respectively, in the presence of an agent or agents 
(chemical or electrical) that promote the fusion of cell 
membranes. Fusion methods using Sendai virus have been 
described (Kohler and Milstein, 1975; 1976), and those 
using polyethylene glycol (PEG), such as 37% (v/v) PEG, 
by Gefter et al. (1977). The use of electrically induced fusion 
methods is also appropriate (Goding, 1986). 
Antibodies, both polyclonal and monoclonal, Specific for 
the eukaryotic fusion proteins may be prepared using con 
ventional immunization techniques, as will be generally 
known to those of skill in the art. A composition containing 
antigenic epitopes of particular eukaryotic fusion protein can 
be used to immunize one or more experimental animals, 
Such as a rabbit or mouse, which will then proceed to 
produce Specific antibodies against epitope-containing 
eukaryotic fusion proteins. Polyclonal antisera may be 
obtained, after allowing time for antibody generation, Sim 
ply by bleeding the animal and preparing Serum Samples 
from the whole blood. 
When peptides are used as antigens to raise polyclonal 
Sera, one would expect considerably leSS Variation in the 
clonal nature of the Sera than if a whole antigen were 
employed. Unfortunately, if incomplete fragments of an 
epitope are presented, the peptide may very well assume 
multiple (and probably non-native) conformations. As a 
result, even short peptides can produce polyclonal antisera 
with relatively plural Specificities and, unfortunately, an 
antisera that does not react or reacts poorly with the native 
molecule. 
Polyclonal antisera according to present invention is 
produced against peptides that are predicted to comprise 
whole, intact epitopes. It is believed that these epitopes are, 
therefore, more stable in an immunologic Sense and thus 
express a more consistent immunologic target for the 
immune System. Under this model, the number of potential 
B-cell clones that will respond to this peptide is considerably 
Smaller and, hence, the homogeneity of the resulting Sera 
will be higher. In various embodiments, the present inven 
tion provides for polyclonal antisera where the clonality, i.e., 
the percentage of clone reacting with the same molecular 
determinant, is at least 80%. Even higher clonality-90%, 
95% or greater is contemplated. 
It is proposed that the monoclonal antibodies of the 
present invention will find useful application in Standard 
immunochemical procedures, Such as ELISA and Western 
blot methods, as well as other procedures which may utilize 
antibody Specific to the particular epitopes. Additionally, it 
is proposed that monoclonal antibodies specific to the par 
ticular eukaryotic fusion peptide may be utilized in other 











Sorbent protocols may be useful in purifying native or 
recombinant peptide Species or Synthetic or natural variants 
thereof. In general, both poly- and monoclonal antibodies 
against these peptides may be used in a variety of embodi 
ments. For example, they may be employed in antibody 
cloning protocols to obtain cDNAS or genes encoding the 
peptides disclosed herein or related proteins. They may also 
be used in inhibition studies to analyze the effects of 
particular peptides in cells or animals. A particularly useful 
application of Such antibodies is in purifying the fusion 
protein, for example, using an antibody affinity column. The 
operation of all Such immunological techniques will be 
known to those of skill in the art in light of the present 
disclosure. 
4.14 DETECTION OF PEPTIDE AND ANTIBODY COMPOSITIONS 
It will be further understood that certain of the polypep 
tides may be present in quantities below the detection limits 
of typical Staining procedures Such as Coomassie brilliant 
blue or Silver Staining, which are usually employed in the 
analysis of SDS/PAGE gels, or that their presence may be 
masked by an inactive polypeptide of similar M. Although 
not necessary to the routine practice of the present invention, 
it is contemplated that other detection techniques may be 
employed advantageously in the visualization of particular 
polypeptides of interest. Immunologically-based techniques 
Such as Western blotting using enzymatically-, radiolabel-, 
or fluorescently-tagged antibodies described herein are con 
sidered to be of particular use in this regard. Alternatively, 
the peptides of the present invention may be detected by 
using antibodies of the present invention in combination 
with Secondary antibodies having affinity for Such primary 
antibodies. This Secondary antibody may be enzymatically 
or radiolabeled, or alternatively, fluorescently-, or colloidal 
gold-tagged. Means for the labeling and detection of Such 
two-step Secondary antibody techniques are well-known to 
those of skill in the art. 
4.15 PROTEIN PURIFICATION METHODS 
Further aspects of the present invention concern the 
purification, and in particular embodiments, the Substantial 
purification, of the recombinant eukaryotic fusion proteins 
produced in bacterial host cells. The phrase “purified pro 
tein’ as used herein, is intended to refer to a polypeptide 
composition, isolatable from the Soluble fraction or cell 
culture Supernatant of a recombinant bacterial cell, wherein 
the protein is purified to any degree relative to its naturally 
obtainable State, i.e., in this case, relative to its purity within 
the Soluble fraction or cell culture Supernatant of a recom 
binant bacterial cell. A purified protein, therefore, also refers 
to isolated protein, free from the environment in which it 
may naturally occur. 
Generally, “purified” will refer to a protein composition 
which has been Subjected to fractionation to remove various 
non-polypeptide components, and which composition Sub 
Stantially retains its normal ability. For example, in the case 
of enzymes such as t?A or BPTI, that the purified protein 
retain its biological or enzymatic activity. Where the term 
“substantially purified” is used, this will refer to a compo 
sition in which F factor forms the major component of the 
composition, Such as constituting from about 50% to about 
60% of the protein in the composition or more. 
Various methods for quantifying the degree of purification 
of the recombinant polypeptides of the present invention 
will be known to those of skill in the art in light of the 
present disclosure. These include, for example, determining 
the Specific activity of an active fraction, or assessing the 
number of polypeptides within a fraction by SDS/PAGE 
analysis. A preferred method for assessing the purity of the 
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protein fraction is to calculate the Specific activity of the 
fraction, to compare it to the Specific activity of the initial 
Source (e.g., the Soluble fraction or cell culture Supernatant, 
and to thus calculate the degree of purity, herein assessed by 
a “-fold purification number.”The actual units used to rep 
resent the amount of inhibitory activity will, of course, be 
dependent upon the particular assay technique chosen to 
follow the purification. For example, in the case of tRA, the 
inventors prefer to use a commercially-available chromoge 
nic assay (SPECTROLYSETM, American Diagnostics, Inc., 
Greenwich, TC). 
Likewise, in the case of BPTI, the inventors have quan 
titated the enzyme using the ELISA assay as described in 
Section 5. 
AS is generally known in the art, to determine the Specific 
activity, one would calculate the number of units of activity 
per milligram of total protein. In the purification procedure, 
the Specific activity of the Starting material, i.e., of the 
Soluble fraction or culture Supernatant containing the desired 
recombinant, would represent the Specific activity of the 
protein in its natural State. At each Step, one would generally 
expect the Specific activity of the protein to increase above 
this value, as it is purified relative to its natural State. In 
preferred embodiments, it is contemplated that one would 
assess the degree of purity of a given protein fraction by 
comparing its specific activity to the Specific activity of the 
Starting material, and representing this as X-fold purifica 
tion. The use of "-fold purification' is advantageous as the 
purity of an inhibitory fraction can thus be compared to 
another despite any differences which may exist in the actual 
units of activity or Specific activity. 
It is contemplated that the eukaryotic fusion polypeptides 
of the present invention be purified to between about 10-fold 
and about 200-fold, and preferably, between about 30-fold 
and about 150-fold. 
Generally, "purified’ will refer to a composition compris 
ing a eukaryotic fusion protein which has been Subjected to 
fractionation to remove various non-polypeptide compo 
nents Such as other cell components. Various techniques 
suitable for use in protein purification will be well known to 
those of skill in the art. These include, for example, pre 
cipitation with ammonium sulfate, PEG, antibodies and the 
like or by heat denaturation, followed by centrifugation; 
chromatography StepS. Such as ion eXchange, gel filtration, 
reverse phase, hydroxylapatite and affinity chromatography; 
isoelectric focusing, gel electrophoresis, and combinations 
of Such and other techniques. A specific example presented 
herein is the purification of the proteins using gel filtration 
chromatography. 
The preferred purification method disclosed hereinbelow 
contains Several StepS and represents the best mode presently 
known by the inventors to prepare a Substantially purified 
protein. This method is currently preferred as it results in the 
Substantial purification of the polypeptide, as assessed by gel 
filtration, in yields Sufficient for further characterization and 
use. This preferred mode of protein purification involves the 
execution of certain purification Steps in the order described 
hereinbelow. However, as is generally known in the art, it is 
believed that the order of conducting the various purification 
StepS may be changed, or that certain Steps may be omitted, 
and Still result in a Suitable method for the preparation of a 
Substantially purified recombinant protein. 
AS mentioned above, although preferred for use in certain 
embodiments, there is no general requirement that the pro 
tein always be provided in its most-purified State. Indeed, it 
is contemplated that leSS Substantially purified proteins, 











protein activity relative to the natural State, will have utility 
in certain embodiments. For example crude tRA may be 
employed in assay kits for determining the activity of tRA 
inhibitors. Similarly, BPTI may be employed to detect 
trypsin activity. 
One important technique in the art for the purification of 
polypeptides is the method of affinity chromatography. 
Affinity chromatography is generally based on the recogni 
tion of a protein by a Substance Such as a ligand or an 
antibody. The column material may be synthesized by 
covalently coupling a binding molecule, Such as an activated 
dye, for example to an insoluble matrix. The column mate 
rial is then allowed to adsorb the desired Substance from 
Solution. Next, the conditions are changed to those under 
which binding does not occur and the Substrate is eluted. The 
requirements for Successful affinity chromatography are: 
1) that the matrix must specifically-adsorb the molecules 
of interest; 
2) that other contaminants remain unadsorbed; 
3) that the ligand must be coupled without altering its 
binding activity; 
4) that the ligand must bind sufficiently tight to the matrix; 
and 
5) that it must be possible to elute the molecules of 
interest without destroying them. 
A preferred embodiment of the present invention is an 
affinity chromatography method for purification of the 
recombinant eukaryotic polypeptides from Solution 
(including cell culture Supernatant, and cell Soluble extracts) 
wherein the matrix contains an antibody Specific for the 
particular polypeptide, covalently-coupled to a Sepharose 
CL6B or CL4B. Such an affinity matrix would then bind the 
polypeptides of the present invention directly and allows 
their separation by elution with an appropriate gradient Such 
as a buffer, salt, GuHCl, pH, or urea. 
4.16 CHROMATOGRAPHY AND SDS-PAGE OF THE RECOMBI 
NANT POLYPEPTIDES 
The recombinant polypeptides of the present invention 
may be particularly characterized based on a number of 
physical, chemical, and biophysical properties. For example, 
the molecular weight of a given protein may be determined 
using conventional means known to those of Skill in the art, 
e.g. as determined by gel filtration column chromatography. 
Gel filtration chromatography is a means of determining 
molecular weight of protein species, and is a well-known 
technique. In general, a preferred gel to be used in the 
procedures of the present invention is a three dimensional 
network which has a random Structure. Molecular Sieve gels 
consist of croSS-linked polymers that do not bind or react 
with the material being analyzed or Separated. For gel 
filtration purposes, the gel material is generally uncharged. 
The space within the gel is filled with liquid and the liquid 
phase constitutes the majority of the gel Volume. Materials 
commonly used in gel filtration columns include dextran, 
agarose and polyacrylamide. 
DeXtran is a polysaccharide composed of glucose residues 
and is commercially available under the names SEPHADEX 
(Phamacia Fine Chemicals, Inc.). The beads are prepared 
with various degrees of croSS-linking in order to Separate 
different sized molecules by providing various pore sizes. 
The size of the croSS-linking molecule can also be increased 
to obtain larger pore sizes. Alkyl dextran is cross-linked with 
N, N'-methylenebisacrylamide to from SEPHACRYL-S300 
which allows Strong beads to be made that fractionate in 
larger ranges than SEPHADEX can achieve. 
The most preferred method of gel filtration in the present 
invention is agarose gel filtration. Agarose is a linear poly 
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mer of D-galactose and 3.6 anhydro-1-galactose and the gel 
polymer is formed by hydrogen bonds. In gel filtration 
applications the agarose is provided as porous beads and the 
concentration of agarose determines pore size. This type of 
gel is useful for the Separation of large, globular molecules 
Such as proteins and for long linear molecules Such as DNA. 
Agarose is commercially available under the name 
Sepharose (Sigma) in Several pore sizes. In the procedures 
of the present invention, SEPHAROSE 4B which fraction 
ates in the molecular weight range of 3x10 to 3x10° is the 
most preferred agarose preparation. 
Polyacrylamide is a polymer of croSS-linked acrylamide 
prepared with N, N'-methylenebisacrylamide as the cross 
linking agent. Polyacrylamide is available in a variety of 
pore sizes from Bio-Rad Laboratories (USA) to be used for 
Separation of different size particles. 
The gel material Swell in water and in a few organic 
Solvents. Swelling is the process by which the pores become 
filled with liquid to be used as eluant. As the smaller 
molecules enter the pores, their progreSS through the gel is 
retarded relative to the larger molecules which do not enter 
the pores. This is the basis of the separation. The beads are 
available in various degrees of fineness to be used in 
different applications. The coarser the bead, the faster the 
flow and the poorer the resolution. Superfine is to be used for 
maximum resolution, but the flow is very slow. Fine is used 
for preparative work in large columns which require a faster 
flow rate. The coarser grades are for large preparations in 
which resolution is leSS important than time, or for Separa 
tion of molecules with a large difference in molecular 
weights. 
However, it is, of course, generally understood by those of 
skill in the art that both the migration of a polypeptide using 
SDS/PAGE, and the mobility of a polypeptide using differ 
ent sizing columns can vary with different experimental 
conditions (Capaldi et al., 1977). It will therefore be appre 
ciated that under differing electrophoretic and chromato 
graphic conditions, the molecular weight assignments 
quoted above may vary. 
It will be further understood that certain of the polypep 
tides may be present in quantities below the detection limits 
of the Coomassie brilliant blue Staining procedure usually 
employed in the analysis of SDS/PAGE gels, or that their 
presence may be masked by an inactive polypeptide of 
Similar Mr. Although not necessary to the routine practice of 
the present invention, it is contemplated that other detection 
techniques may be employed advantageously in the Visual 
ization of each of the polypeptides present within the growth 
factor. Immunologically-based techniques Such as Western 
blotting using enzymatically-, radiolabel-, or fluorescently 
tagged Secondary antibodies are considered to be of particu 
lar use in this regard. 
4.17 MODES FOR CARRYING OUT THE INVENTION 
In the process herein, expression of the pdi gene is 
induced just before (immediately prior to) heterologous gene 
expression. The heterologous eukaryotic polypeptide and 
the PDI or rPDI protein are both secreted into the periplasm 
or the heterologous polypeptide is Secreted into the culture 
medium of the bacteria into which nucleic acid encoding 
these polypeptides has been introduced. Preferably, the 
polypeptide is recovered from the periplasm of the bacteria. 
The pdi nucleic acid may be from any eukaryotic Source, 
but preferably human, rat, or yeast, and is generally the 
native Sequence. It is Suitably Separately placed from the 
nucleic acid encoding the heterologous polypeptide if 
nucleic acids are on the same vector, i.e., they are not linked. 











acid encoding the heterologous polypeptide are under 
Separate, different inducible promoters So that induction of 
expression can occur in the required Sequential order. The 
nucleic acid encoding PDI and the nucleic acid encoding the 
heterologous polypeptide may be integrated into the host 
cell genome or contained on autonomously replicating plas 
mids. 
In one alternative, the recombinant host cell comprises 
two separate vectors respectively containing the nucleic acid 
encoding PDI and the nucleic acid encoding the heterolo 
gous polypeptide. 
In another alternative, the nucleic acid encoding PDI and 
the nucleic acid encoding the heterologous polypeptide are 
contained on the same vector but are under the control of 
Separate inducible promoters and Separate Signal Sequences. 
The heterologous nucleic acid (e.g., cDNA or genomic 
DNA) is suitably inserted into a replicable vector for expres 
Sion in the bacterium under the control of a Suitable pro 
moter for bacteria. Many vectors are available for this 
purpose, and Selection of the appropriate vector will depend 
mainly on the size of the nucleic acid to be inserted into the 
vector and the particular host cell to be transformed with the 
vector. Each vector contains various components depending 
on its function (amplification of DNA or expression of 
DNA) and the particular host cell with which it is compat 
ible. The vector components for bacterial transformation 
generally include, but are not limited to, one or more of the 
following: a signal Sequence, an origin of replication, one or 
more marker genes, and an inducible promoter. 
In general, plasmid vectors containing replicon and con 
trol Sequences that are derived from Species compatible with 
the host cell are used in connection with bacterial hosts. The 
Vector ordinarily carries a replication site, as Well as marking 
Sequences that are capable of providing phenotypic Selection 
in transformed cells. 
The DNA encoding the polypeptide of interest herein may 
be expressed not only directly, but also as a fusion with 
another polypeptide, preferably a Signal Sequence or other 
polypeptide having a Specific cleavage Site at the N-terminus 
of the mature polypeptide. In general, the Signal Sequence 
may be a component of the vector, or it may be a part of the 
polypeptide DNA that is inserted into the vector. The het 
erologous signal Sequence Selected Should be one that is 
recognized and processed (i.e., cleaved by a signal 
peptidase) by the host cell. For bacterial host cells that do not 
recognize and process the native polypeptide Signal 
Sequence, the Signal Sequence is Substituted by a bacterial 
Signal Sequence Selected, for example, from the group 
consisting of the alkaline phosphatase, penicillinase, lipp, or 
heat-stable enterotoxin II leaders. 
Both expression and cloning vectors contain a nucleic 
acid Sequence that enables the vector to replicate in one or 
more Selected host cells. Generally, in cloning vectors this 
Sequence is one that enables the vector to replicate indepen 
dently of the host chromosomal DNA, and includes origins 
of replication or autonomously replicating Sequences. Such 
Sequences are well known for a variety of bacteria. The 
origin of replication from either pBR322 or paCYC184 is 
Suitable for most Gram-negative bacteria. 
Expression and cloning vectors also generally contain a 
Selection gene, also termed a Selectable marker. This gene 
encodes a protein necessary for the Survival or growth of 
transformed host cells grown in a Selective culture medium. 
Host cells not transformed with the vector containing the 
Selection gene will not Survive in the culture medium. 
Typical Selection genes encode proteins that (a) confer 
resistance to antibiotics or other toxins, e.g., amplicillin, 
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neomycin, methotrexate, or tetracycline, (b) complement 
auxotrophic deficiencies, or (c) Supply critical nutrients not 
available from complex media, e.g., the gene encoding 
D-alanine racemase for Bacilli. One example of a Selection 
Scheme utilizes a drug to arrest growth of a host cell. Those 
cells that are Successfully transformed with a heterologous 
gene produce a protein conferring drug resistance and thus 
Survive the Selection regimen. 
The expression vector for producing a heterologous 
polypeptide also contains an inducible promoter that is 
recognized by the host bacterial organism and is operably 
linked to the nucleic acid encoding the polypeptide of 
interest. It also contains a separate inducible promoter 
operably linked to the nucleic acid encoding PDI. Inducible 
promoters suitable for use with bacterial hosts include the 
b-lactamase and lactose (lac) promoter Systems (Chang et 
al., 1978; Goeddelet al., 1979), the arabinose (ara) promoter 
System (Guzman et al., 1992), alkaline phosphatase (phoA), 
a tryptophan (trp) promoter system (Goeddel, 1980; Eur. 
Pat. Appl. Publ. No. EP36,776), 2 promoter, and hybrid 
promoters such as the tac promoter (deBoer et al., 1983). 
However, other known bacterial inducible promoters are 
Suitable. Their nucleotide Sequences have been published, 
thereby enabling a skilled worker operably to ligate them to 
DNA encoding the polypeptide of interest or to the pdi gene 
(Siebenlist et al., 1980) using linkers or adaptors to Supply 
any required restriction sites. 
Promoters for use in bacterial Systems also generally 
contain a Shine-Dalgarno (S.D.) Sequence operably linked to 
the DNA encoding the polypeptide of interest. The promoter 
can be removed from the bacterial source DNA by restric 
tion enzyme digestion and inserted into the vector contain 
ing the desired DNA. Construction of Suitable vectors con 
taining one or more of the above-listed components employs 
Standard ligation techniques. Isolated plasmids or DNA 
fragments are cleaved, tailored, and re-ligated in the form 
desired to generate the plasmids required. 
For analysis to confirm correct Sequences in plasmids 
constructed, the ligation mixtures are used to transform E. 
coli K12 strain 294 (ATCC 31446), SF103, SF110, UT5600, 
RB791, or any other suitable strain, and successful trans 
formants are Selected using antibiotic resistance where 
appropriate. Plasmids from the transformants are prepared, 
analyzed by restriction endonuclease digestion, and/or 
sequenced by the method of Sanger et al. (1977) or Messing 
et al. (1981) or by the method of Maxam et al. (1980). 
Suitable bacteria for this purpose include Archaebacteria 
and Eubacteria, especially Eubacteria, and most preferably 
Enterobacteriaceae. Examples of useful bacteria include 
Escherichia, Enterobacter, AZotobacter, Erwinia, Bacillus, 
Pseudomonas, Klebsiella, Proteus, Salmonella, Serratia, 
Shigella, Rhizobia, Vitreoscilla, and Paracoccus. Suitable E. 
coli hosts include E. coli SF103, SF110, UT5600, RB791, 
W3110 (ATCC 27325), E. coli 294 (ATCC 31446), E. coli 
B, and E. coli '77 (ATCC 31537). These examples are 
illustrative rather than limiting. Mutant cells of any of the 
above-mentioned bacteria may also be employed. It is, of 
course, necessary to Select the appropriate bacteria taking 
into consideration replicability of the replicon in the cells of 
a bacterium. For example, E. coli, Serratia, or Salmonella 
Species can be Suitably used as the host when well known 
plasmids such as pBR322, pBR325, p.ACYC177, or 
pKN410 are used to supply the replicon. 
E. coli strains Such as ATCC 98.380, or those disclosed in 
U.S. Pat. No. 5,508,192 (SF103, SF110, UT5600, and 
RB791) are preferred hosts or parent hosts for the practice 











binantly engineered host cells which provide excellent 
recovery of recombinant polypeptides. Preferably, the host 
cell should Secrete minimal amounts of proteolytic enzymes. 
Alternatively, other E. coli Strains, for example, E. coli Strain 
W3110, may be modified to effect a genetic mutation in the 
genes encoding proteins, with examples of Such hosts 
including E. coli W3110 strain 1A2, which has the complete 
genotype tonAD; E. coli W3110 strain 9E4, which has the 
complete genotype tonAD ptr3, E. coil W3110 strain 27C7 
(ATCC 55,244), which has the complete genotype tonAD 
ptr3 phoADE15 D(argF-lac)169 ompTD degP41kan', E. 
coil W3110 strain 37D6, which has the complete genotype 
tonAD ptr3 phoADE 15 D(argF-lac) 169 ompTD degP41kan' 
rbs7D ilvO; Ecoli W3110 strain 40B4, which is strain 37D6 
with a non-kanamycin resistant degP deletion mutation, E. 
coli W3110 strain 33D3, which has the complete genotype 
ton Aptr3 lacIq LacL8 ompT degP kani E. coil W3110 
Strain 36F8, which has the complete genotype tonA phoA 
D(argF-lac) ptr3 degP kan' ilvG", and is temperature resis 
tant at 37 C.; and an E. coil strain having the mutant 
periplasmic protease(s) disclosed in U.S. Pat. No. 4,946,783. 
Host cells are transfected and preferably transformed with 
the above-described expression vectors and cultured in 
conventional nutrient media modified as appropriate for 
inducing promoters, Selecting transformants, or amplifying 
the genes encoding the desired Sequences. 
Transfection refers to the taking up of an expression 
vector by a host cell whether or not any coding Sequences 
are in fact expressed. Numerous methods of transfection are 
known to the ordinarily skilled artisan, for example, CaPO 
and electroporation. Successful transfection is generally 
recognized when any indication of the operation of this 
vector occurs within the host cell. 
Transformation means introducing DNA into an organism 
so that the DNA is replicable, either as an extrachromosomal 
element or by chromosomal integrant. Depending on the 
host cell used, transformation is done using Standard tech 
niques appropriate to Such cells. The calcium treatment 
employing calcium chloride, as described in Section 1.82 of 
Sambrook et al., (1989), is generally used for bacterial cells 
that contain Substantial cell-wall barriers. Another method 
for transformation employs polyethylene glycol/DMSO, as 
described in Chung and Miller (1988). Yet another method 
is the use of the technique termed electroporation. 
Bacterial cells used to produce the polypeptide of interest 
for purposes of this invention are cultured in Suitable media 
in which the promoters for the nucleic acid encoding the 
heterologous polypeptide and for the nucleic acid encoding 
PDI can be artificially induced as described generally, e.g., 
in Sambrook et al (1989). Examples of suitable media are 
given in U.S. Pat. Nos. 5,304,472 and 5,342,763. 
Any necessary Supplements besides carbon, nitrogen, and 
inorganic phosphate Sources may also be included at appro 
priate concentrations introduced alone or as a mixture with 
another Supplement or medium Such as a complex nitrogen 
Source. The pH of the medium may be any pH from about 
5-9, depending mainly on the host organism. Optionally the 
culture medium may contain one or more reducing agents 
Selected from the group consisting of glutathione, cysteine, 
cyStamine, thioglycollate, dithioerythritol, dithiothreitol and 
dithioerythritol. Preferably, the bacteria arc not cultured so 
as to over-express nucleic acid encoding the heat-shock 
transcription factor, RpoH. 
For induction, typically the cells are cultured until a 
certain optical density is achieved, e.g., a Asso of about 
60-80, at which point induction is initiated (e.g., by addition 
of an inducer, by depletion of a medium component, etc.), to 
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induce expression of the pdigene. When the optical density 
reaches a higher amount, e.g., a Asso of about 80–100, 
induction of the Second promoter for the heterologous 
polypeptide is effected. 
Gene expression may be measured in a Sample directly, 
for example, by conventional northern blotting to quantitate 
the transcription of mRNA (Thomas, 1980). Various labels 
may be employed, most commonly radioisotopes, particu 
larly P. However, other techniques may also be employed, 
Such as using biotin-modified nucleotides for introduction 
into a polynucleotide. The biotin then serves as the site for 
binding to avidin or antibodies, which may be labeled with 
a wide variety of labels, Such as radionuclides, fluorescers, 
enzymes, or the like. 
Procedures for observing whether an expressed or over 
expressed gene product is Secreted are readily available to 
the skilled practitioner. Once the culture medium is sepa 
rated from the host cells, for example, by centrifugation or 
filtration, the gene product can then be detected in the 
cell-free culture medium by taking advantage of known 
properties characteristic of the gene product. Such properties 
can include the distinct immunological, enzymatic, or physi 
cal properties of the gene product. 
For example, if an over-expressed gene product has a 
unique enzyme activity, an assay for that activity can be 
performed on the culture medium used by the host cells. 
Moreover, when antibodies reactive against a given gene 
product are available, Such antibodies can be used to detect 
the gene product in any known immunological assay (e.g., 
as in Harlow and Lane, 1988). 
The Secreted gene product can also be detected using tests 
that distinguish polypeptides on the basis of characteristic 
physical properties Such as molecular weight. To detect the 
physical properties of the gene product, all polypeptides 
newly Synthesized by the host cell can be labeled, e.g., with 
a radioisotope. Common radioisotopes that can be used to 
label polypeptides Synthesized within a host cell include 
tritium (H), carbon-14 (''C), sulfur-35 (S), and the like. 
For example, the host cell can be grown in S-methionine 
or S-cysteinc medium, and a significant amount of the S 
label will be preferentially incorporated into any newly 
Synthesized polypeptide, including the over-expressed het 
erologous polypeptide. The S-containing culture medium 
is then removed and the cells are washed and placed in fresh 
non-radioactive culture medium. After the cells are main 
tained in the fresh medium for a time and under conditions 
sufficient to allow secretion of the S-radiolabeled 
expressed heterologous polypeptide, the culture medium is 
collected and Separated from the host cells. The molecular 
weight of the Secreted, labeled polypeptide in the culture 
medium can then be determined by known procedures, e.g., 
polyacrylamide gel electrophoresis. Such procedures, and/or 
other procedures for detecting Secreted gene products, are 
provided in Goeddel (1990), and Sambrook et al. (1989). 
For Secretion of an expressed or over-expressed gene 
product, the host cell is cultured under conditions Sufficient 
for Secretion of the gene product. Such conditions include, 
e.g., temperature, nutrient, and cell density conditions that 
permit Secretion by the cell. Moreover, Such conditions are 
those under which the cell can perform basic cellular func 
tions of transcription, translation, and passage of proteins 
from one cellular compartment to another, as are known to 
those skilled in the art. 
In practicing the process of this invention, the yield of 
total polypeptide is generally increased, while yield of 
insoluble polypeptide is not changed or is decreased, i.e., 











The polypeptide of interest is recovered from the peri 
plasm or culture medium as a Secreted Soluble polypeptide. 
It is often preferred to purify the polypeptide of interest from 
recombinant cell proteins or polypeptides and from PDI to 
obtain preparations that are Substantially homogeneous as to 
the polypeptide of interest. As a first Step, the culture 
medium or lysate is centrifuged to remove particulate cell 
debris. The membrane and soluble protein fractions may 
then be separated if necessary. The polypeptide may then be 
purified from the soluble protein fraction and from the 
membrane fraction of the culture lysate, depending on 
whether the polypeptide is membrane associated or, more 
preferably, completely Soluble in the periplasm or culture 
Supernatant. The polypeptide thereafter may be further Solu 
bilized and/or refolded, if necessary, and purified from 
contaminant Soluble proteins and polypeptides. 
The types of phase-forming species to employ herein 
depend on many factors, including the type of polypeptide 
and the ingredients in the fermentation broth being treated. 
The Species must be Selected So that the polypeptide does not 
precipitate and one phase is more hydrophobic than the other 
phase So that the polypeptide will be located in the more 
hydrophobic phase and the biomass Solids and nucleic acids 
will settle to the less hydrophobic phase. 
The phase-forming Species may be a combination of 
agents, including polymer combinations (polymer-polymer), 
polymer-Salt combinations, Solvent-salt, and polymer 
solvent combinations. Suitable polymers are both highly 
hydrophilic polymers and less hydrophilic polymers, i.e., 
any phase-forming polymers that are known in the art. 
Examples include polyethylene glycol or derivatives 
thereof, including various molecular weights of PEG Such as 
PEG 4000, PEG 6000, and PEG 8000, derivatives of PEG 
described, for example, in Grunfeld et al. (1992), polyvi 
nylpyrrolidone (PVP), in a preferable molecular weight 
range of about 36,000 to 360,000, starches such as dextran 
(e.g., dextran 70 and 500), dextrins, and maltodextrins 
(preferable molecular weight between about 600 and 5,000), 
sucrose, and FICOLL-400TM polymer (a copolymer of 
Sucrose and epichlorohydrin). The preferred polymer herein 
is polyethylene glycol, polypropylene glycol, 
polyvinylpyrrollidone, or a polysaccharide Such as a dextran. 
The most preferred polymer herein is PEG of different 
molecular weights or a PEG-polypropylene glycol combi 
nation or copolymer. 
Examples of Suitable organic Solvents include ethylene 
glycol, glycerol, dimethyl Sulfoxide, polyvinylalcohol, 
dimethylformamide, dioxane, and alcohols Such as 
methanol, ethanol, and 2-propanol. Such Solvents are Such 
that, when added to aqueous Solution, they increase the 
hydrophobicity of the solution. 
The Salts can be inorganic or organic and preferably do 
not act to precipitate the polypeptide. Salts containing tran 
Sition elements are not preferred as they tend to precipitate 
the polypeptide. Anions are Selected that have the potential 
for forming aqueous multiple-phase Systems. Examples 
include ammonium Sulfate, Sodium dibasic phosphate, 
Sodium Sulfate, ammonium phosphate, potassium citrate, 
magnesium phosphate, Sodium phosphate, calcium 
phosphate, potassium phosphate, potassium Sulfate, magne 
sium Sulfate, calcium Sulfate, Sodium citrate, manganese 
Sulfate, manganese phosphate, etc. Types of Salts that are 
useful in forming bi-phasic aqueous Systems are evaluated 
more fully by Zaslavskii et al. (1988). Preferred salts herein 
are Sulfates, phosphates, or citrates and are alkali or alkaline 
earth metals. More preferred are Sulfates and citrates, and 
most preferred are Sulfates Since there are fewer pH limita 
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tions with sulfates. The most preferred salts herein are 
Sodium Sulfate and Sodium citrate. 
The amounts of phase-forming Species to add to the 
polypeptide of interest to obtain a Satisfactory multiple 
phase System are those known in the art. The amount of 
phase-forming species added to the polypeptide will depend 
on Such factors as, for example, the amount of chaotropic 
agent and reducing agent, if any, already present in the 
fermentation broth, the nature of the cell culture media, the 
type of cells used in the fermentation, the type of polypep 
tide being treated, whether the polypeptide will be recovered 
from the lower or upper phase, and the type(s) of phase 
forming Species being added. The general concentration of 
polymer employed is about 5% (w/w) up to the limit of 
solubility for the polymer and the concentration of salt 
employed is about 3% (w/w) up to the limit of solubility for 
the Salt, depending on the size of the phase-Volume ratio 
needed. The phase-Volume ratio must be Sufficient to accom 
modate the biomass Solids. The types and amounts of 
phase-forming species that are effective can be determined 
by phase diagrams and by evaluating the final result, i.e., the 
degree of purity and the yield of the polypeptide of interest. 
If the phase-forming Species are a polymer-Salt combination, 
preferably the concentration of salt added is about 4-15% 
(wt./wt.) and the concentration of polymer is 5-18% (wt./ 
wt.) So that the desired polypeptide will be in an opposite 
phase from that in which the biomass Solids and nucleic 
acids are present. 
If the System desired is one where the polypeptide is 
distributed in the top phase and the biomass Solids and 
nucleic acids are in the bottom phase, then there is a window 
of concentrations of phase-forming Species. When higher 
amounts of chaotropic agent are added to maintain 
Solubilization, the higher the amount of phase-forming Spe 
cies required. However, a high concentration of all these 
reagents will increase the density of the Solution. A high 
density will cause the biomass Solids to Settle leSS readily. 
An overly high density will cause biomass Solids to float on 
the Surface. Hence, the concentrations of chaotropic agent 
and phase-forming Species must be Sufficiently high to 
maintain a fully Solubilized polypeptide, but low enough to 
allow the biomass Solids to Sediment to the opposite (lower) 
phase. 
If the polypeptide is to be recovered in the upper phase, 
typically the salt concentration will be about 4-7% (wt./wt.) 
and the polymer concentration will be about 12–18% (wt./ 
Wt.), depending, e.g., on the type of Salt, polymer, and 
polypeptide. If an organic Solvent is added as a phase 
forming Species, Such as ethanol, it is preferably added in a 
concentration of about 10 to 30% (vol./vol.) of the solution, 
depending, e.g., on the type of polypeptide and alcohol and 
if any other phase-forming Species is present, preferably at 
a concentration of about 20% (vol./vol.). 
The exact conditions for contacting the cell culture with 
the various reagents will depend on, e.g., the pH of the 
buffer, the types of phase-forming reagents, and the types 
and concentrations of polypeptide and chaotropic and reduc 
ing agents. The reaction temperature is generally about 20 to 
about 40 C., more preferably room temperature. The con 
tacting Step will generally be carried out for at least about 30 
min., preferably about 30 min. to about 12 hr depending on 
whether side-reactions will occur, more preferably about 30 
min. to about 8 hr, and most preferably about 30 min. to 
about 1.5 hr. 
Once the multiple-phase System is established, one phase 
will be enriched in the polypeptide and depleted in the 











and nucleic acids. In a two-phase System, preferably the top 
phase is enriched in the polypeptide whereas the bottom 
phase is enriched in the disrupted particles and cells. The 
polypeptide can be easily recovered by Separation of the 
phases. This recovery Step may be accomplished by decant 
ing the upper phase, by draining the lower phase, or by 
centrifugation. The polypeptide can then be isolated from 
the phase in which it is contained by changing the pH of the 
phase So as to precipitate the polypeptide or by adding a 
Suitable Solvent, whereupon the precipitated polypeptide is 
Suitably recovered by centrifugation or filtration or as a 
Slurry. Alternatively, the polypeptide can be recovered from 
the polymer-containing phase by re-extraction by addition of 
a suitable polymer, salt, or solvent. The PDI protein may 
also be separated from the recombinant tRA or PTI polypep 
tide at this stage. 
Once obtained from the liquid phase of the multiple-phase 
System, or at a later Stage of purification, the polypeptide 
may be suitably stored in an appropriate buffer. The buffer 
can be any buffer known to those of skill in the art to 
preserve the biological activity and integrity of the isolated 
recombinant polypeptide. Such buffers include those listed 
below in Section 5, or alternatively, CAPSO, glycine, CAPS, 
MOPS, HEPES, etc. may be employed preferably at a pH of 
from between about pH 6 and pH 11, particularly at a 
concentration of about 20 mM. The polypeptide may be 
diluted with the buffer, or alternatively, the polypeptide may 
be dialyzed against fresh buffer. 
5. EXAMPLES 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventors to function well in the practice 
of the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the Specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the Spirit and Scope of the invention. 
5.1 EXAMPLE 1-PRODUCTION OF BPTI IN E. COLI HOST 
CELLS 
The present work shows that rat rPDI expressed in the E. 
coli periplasmic space is able to catalyze the formation of 
disulfide bonds in bacterial proteins, and to complement 
Several of the phenotypes of dsbA mutants. Expression of 
rPDI in the E. coli periplasm enhances expression of the 
recombinant multi-disulfide pancreatic trypsin inhibitor, 
BPTI. 
5.1.1 MATERIALS AND METHODS 
5.1.1.1 BACTERIAL STRAINS AND PLASMIDS 
The E. coli K12 strains used were JCB570 MC1000 
phoR Zihl2::Tn 10), JCB571. JCB570 disbA::kan1), JCB789 
JCB570 disbB::kan), JCB758 JCB570 disbA::kan 
dsbB::kan), JCB502(ID69), lacZ:Tn 10 (Tet by fusaric 
acid) and JCB572 JCB502 dsbA::kan1 (Bardwell et al., 
1991; Bardwell et al., 1993). The last two strains contained 
FproAB, lacq, lacZ AM15, Tn10. pTI103 contains the 
Omp A leader-BPTI gene fusion and has been described 
previously (Goldenberg, 1988), pIPPsOmpArPDI contains 
the gene for the mature rat PDI, fused to the Omp A signal 
Sequence, under the control of the lpp-lac promoter (De 
Sutter et al., 1994).p.ACYCBPTI contains the OmpA leader 




5.1.1.2 GENERAL METHODS 
Unless otherwise specified, cells were grown at 37 C. in 
M9 minimal salts media, adjusted to pH 7.0, and supple 
mented with 0.2% glucose, and 0.2% casein. For labeling 
Studies, cultures were Supplemented with 50 tug/ml L-amino 
acids except cysteine and methionine instead of casein. 
Amp (50 ug/ml) and/or chloramphenicol (Cam) (40 ug/ml) 
was added as required. In the BPTI production studies, 100 
tug/ml Amp and 170 ug/ml Cam were used to maintain the 
co-transformants. 
Fractionation by osmotic Shock was carried out essen 
tially as described by Neu and Heppel (1965). Sensitivity to 
filamentous phages was tested by diluting overnight 
cultures, grown without IPTG, to an ODoo =0.005, fol 
lowed by infection with phage JB4 (a Cam', M13 
derivative). Subsequently the cells were plated on LB with 
0.2% glucose and 20 tug/ml Cam. Conjugation Studies using 
SF103 (FT AlacX74 galEgalK thirpsL(stra) A phoA(PvulI) 
ptr-32: S2Cam') as the recipient strain were conducted as 
described (Silhavy et al., 1983). Rabbit polyclonal antisera 
against native BPTI (Boehringer-Mannheim) and rPDI were 
prepared using standard protocols (Ausubel et al., 1989). 
5.1.1.3 PULSE-CHASE STUDIES, IMMUNOPRECIPITATION 
AND ELECTROPHORESIS 
For monitoring the oxidative State of alkaline phosphatase 
and OmpA, mid-exponential phase cells were labeled with 
100 uCi/ml TRANSS LABEL (ICN Biomedicals Inc.) for 
45 sec and chased with 20 mM methionine and 3 mM 
cysteine. Samples (1 ml) were withdrawn at various times 
and added to trichloroacetic acid on ice at a final concen 
tration of 10%. The protein pellets obtained by centrifuga 
tion at 12,000xg for 10 min were resuspended in 0.5 ml of 
100 mM Tris-HCl (pH 9.0), 1.5% SDS, 5 mM EDTA and 35 
mM iodoacetamide. Samples were then diluted 4-fold in 
immunoprecipitation buffer (10 mM Tris-HCl, pH 8.0, 0.1% 
TRITON X-100(R), 0.14 M NaCl, and 0.025% NaNs) and 
immunoprecipitated with antisera to alkaline phosphatase 
(from 5' Prime 3' Prime, Boulder, Colo.) and Omp A as 
previously described (Ostermeier and Georgiou, 1994). Oxi 
dized and reduced proteins were resolved by SDS-PAGE in 
20 cm non-reducing gels essentially as described (Pollitt and 
Zalkin, 1983). Pulse-chase studies for following the kinetics 
of folding of BPTI were carried out as previously described 
(Ostermeier and Georgiou, 1994) except the chase contained 
3 mM cysteine. 
5.1.1.4 DETECTION OF BPTI BY ELISA 
Cells were induced with 0.1 mM IPTG at 
ODoo =0.3–0.35, and, for Some Samples, GSH and/or 
GSSG was added twenty min later at the concentrations 
indicated. Five hours after induction, Samples were frozen at 
–70° C., then thawed to 4°C., lysed by French press (20,000 
psi) and fractionated into insoluble and Soluble fractions by 
centrifugation at 12,000xg for 10 min. The protein concen 
tration of the soluble fraction was measured by the Bio-Rad 
Protein Assay (Bio-Rad, Richmond, Calif.). Next, 100 ul of 
Soluble protein diluted to a concentration of 2.5 lug protein/ 
ml in ELISA coating buffer (32 mM NaCO/68 mM 
NaHCO) was added to 96-well plates. After incubation 
overnight at 4 C., the wells were washed three times with 
washing buffer (0.5% Tween-20(R) in phosphate buffer 
saline) and three times with ddHO, blocked with 200 ul of 
2% bovine serum albumin (Boehringer Mannheim) in phos 
phate buffered saline for 1 hour at 37 C., and washed again. 
Subsequently, 100 ul/well of BPTI antisera (diluted 
1:1000 in phosphate buffer saline with 0.05% Tween-20(R) 
and 0.25% bovine serum albumin) was added to the plate 











again as before and 100 ul of goat anti-rabbit horseradish 
peroxidase conjugate (diluted 1:1000 in phosphate buffer 
Saline with 0.05% Tween-200E) and 0.25% bovine Serum 
albumin) was added to each well. After 30 min at 37° C. and 
a final wash, 100 ul of Peroxidase Substrate ABTS (Bio 
Rad) was added. Developing was stopped with 100 ul 2% 
Oxalic acid after 5 min. and the Ao was measured on a 
MR300 MicroElisa Reader (Dynatech Laboratories Inc., 
Chantilly, Va.). The soluble fraction of cells without plasmid 
was spiked with known amounts of BPTI and used as 
Standards. 
5.1.1.5 AFFINITY PRECIPITATION OF BPTI WITH TRYPSIN 
AGAROSE 
Soluble fractions from 1.5 ml culture volume were mixed 
with 1.5 ml of 50 mM Tris HCl (pH 8.0) buffer and 12.5ul 
trypsin-agarose beads (Sigma, 20 units/ml) and incubated on 
a rotator at 4 C. Subsequently, the beads were resuspended 
in SDS loading buffer, boiled for 5 min, centrifuged, and the 
Soluble fractions were loaded onto 16% Tricine SDS-PAGE 
(Novex, San Diego, Calif.). Electrophoresis was carried out 
under reducing conditions. The proteins were then trans 
ferred to a PVDF membrane for 45 min at 2.5 mA/cm using 
the MILLIBLOT-GRAPHITE ELECTROBLOTTER Sys 
tem (Millipore, Bedford, Mass.) and immunologically 
detected with the anti-BPTI primary antibody (1:1000 
dilution) followed by horseradish peroxidase-conjugated 
goat anti-rabbit IgG (1:3000 dilution) (Bio-Rad, Hercules, 
Calif.) (Ausubel et al., 1989). 
5.1.2 RESULTS 
The gene encoding the complete Sequence of mature rat 
PDI has been fused to the bacterial Omp A leader peptide and 
expressed from the Strong lac-lpp promoter (De Sutter et al., 
1994). Even in the absence of the inducer IPTG, a 55-kDa 
band corresponding to the mature rPDI is readily visible in 
SDS-PAGE gels of the osmotic shock fraction of E. coli 
(FIG. 1) and is the only band detected by Western blot 
analysis using rPDI-specific Sera. Upon induction with 0.5 
mM IPTG, rPDI was overexpressed and became the most 
prominent protein in the periplasmic Space. In addition to the 
intact rPDI monomer, a lower molecular weight product, 
designated rPDIf, was evident in induced but not in unin 
duced cultures (FIG. 1). De Sutter et al. (1994) have shown 
that rPDIf corresponds to a polypeptide synthesized from an 
internal translation initiation codon in the rPDI gene. 
Although rPDIf is found predominantly in the spheroplast 
fraction, a portion is released by osmotic shock, as is evident 
from FIG. 1. Western blotting of samples from induced 
cultures also revealed Several minor lower molecular weight 
Species, presumably degradation products. The level of 
expression was identical in both the disbA mutant Strain 
JCB571 and in the isogenic control strain JCB570. 
Furthermore, western blot demonstrated that rPDI produc 
tion was not substantially affected by the disba, disbB or 
dsbAdsbB mutations under either induced or uninduced 
conditions. This is in contrast to other disulfide bond 
containing Secreted proteins Such as alkaline phosphatase, 
f3-lactamase, urokinase and BPTI (Bardwell, 1994; Oster 
meier and Georgiou, 1994). The production of these proteins 
is Substantially reduced in disbA and dsbB mutants, presum 
ably because inefficient formation of disulfide bonds results 
in increased Susceptibility to proteolytic degradation. 
While disbA is not essential for cell viability, null mutants 
exhibit pleiotropic phenotypes including resistance to fila 
mentous phages, impaired motility and conjugation, poor 
growth in minimal media and formation of mucoid colonies 
when grown with Sub-lethal concentrations of antibiotics 
(Bardwell, 1994; Bardwell et al., 1991). As shown in FIG. 
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2A and FIG. 2B, transformation with plPPsOmpArPDI 
resulted in complementation of Several dshA phenotypes. 
Basal expression of rPDI in cells grown without inducer was 
Sufficient to restore conjugation competence and Sensitivity 
to f1 phage to about 20% and 35% of the level in the parental 
strain, respectively. Expression of rPDI also restored the 
growth rate of dsbA cells in minimal media to that of dsbA' 
cells (FIG.2B). Complementation of the disbA phenotypes is 
not merely due to the expression of a heterologous Secreted 
protein Since it was not observed in cells producing 
preC)mpA-BPTI which is also exported in the E. coli peri 
plasmic Space via the OmpA leader peptide and, like rPDI, 
contains six cysteines. It should be noted that in these 
studies, cells were not induced with IPTG because (a) rPDI 
was already expressed at Significant levels without induction 
and (b) the overproduction of rPDI in induced cultures was 
found to negatively affect the efficiency of conjugation in 
wild type cells. 
In Some genetic backgrounds a null dsbA allele confers 
sensitivity to DTT (Missiakas et al., 1993). However, the 
growth of JCB570 and JCB571 were similarly affected by 
the presence of reduced DTT or GSH in both rich and 
minimal media. Thus, in the JCB570 genetic background, it 
was not possible to determine whether the expression of 
rPDI affects the sensitivity of dsbA cells to reducing agents. 
The ability of rPDI to complement the phenotypes of 
dsbA null mutants Suggested that it must be able to catalyze 
the formation of disulfide bonds in the periplasmic Space. 
Direct evidence for the function of rPDI in vivo was 
obtained by examining the kinetics of oxidation of two 
bacterial exported proteins, alkaline phosphatase and 
Omp A. Cultures were radiolabeled with 100 uCi/ml Trans 
Label for 45 sec and then samples were added to iodoac 
etamide at different times to carboxymethylate free cysteine 
residues. Subsequently, reduced and oxidized alkaline phos 
phatase were resolved electrophoretically in 20 cm poly 
acrylamide gels. The formation of disulfide bonds in disbA' 
cells was very rapid and was largely completed within one 
min, whereas in dsbA cells, no oxidized alkaline phos 
phatase was detectable even after 10 min (FIG. 3A). 
However, in cells expressing basal levels of rPDI, the 
formation of disulfide bonds was restored and oxidized 
alkaline phosphatase was the only Species detectable after 10 
min of chase. Transformation with a control plasmid 
(pTI103) did not have any effect on the oxidation state of 
alkaline phosphatase. Similar results were observed with the 
oxidation of the outer membrane protein Omp A which 
contains a Single disulfide bond in the putative C-terminal 
periplasmic domain. 
For PDI to be functional as a direct oxidase, its active site 
must be regenerated through disulfide exchange with an 
appropriate donor/acceptor. Whereas in the ER the redox 
state of PDI is determined by the ratio of reduced to oxidized 
glutathione, there is no evidence for an analogous low 
molecular weight redox buffer in the periplasmic Space. In 
E. coli, the reoxidation of DsbA is thought to be mediated by 
DsbB, a cytoplasmic membrane protein that contains at least 
four, and possibly five, cysteines within two periplasmic 
exposed loops (Guilhot et al., 1995; Bardwell et al., 1993; 
Missiakas et al., 1993; Dailey and Berg, 1993; Jander et al., 
1994), dsbB mutants exhibit a defect in disulfide bond 
formation, though not as Severe as disbA mutants. To deter 
mine whether the active state of rPDI may also be dependent 
on DsbB, the oxidation of alkaline phosphatase was moni 
tored indsbB mutants transformed with p PPs Omp ArPDI. 
In disbB mutants less than 30% of the alkaline phosphatase 











(FIG. 3B). Expression of rPDI was largely unable to rescue 
the formation of oxidized alkaline phosphatase as only 50% 
of the alkaline phosphatase was oxidized after ten min. 
Furthermore, no oxidized protein was detected indsbAdsbB 
double mutants with or without pILPPsOmpArPDI. Further 
evidence of rPDI’s dependence on DsbB came from study 
ing the production of the heterologous protein BPTI. As 
discussed in greater dctail below, although rPDI could 
rescue the formation of BPTI in disbA mutants, rPDI could 
not rescue the formation of BPTI indsbB mutants. Thus, the 
catalysis of disulfide formation by rPDI in E. coli is depen 
dent on a functional dsbB gene. 
In disbB mutants, but not in disbA mutants or in wild type 
cells, the expression of rPDI appeared to mildly interfere 
with the processing of the leader peptide as evidenced by the 
presence of a band corresponding to the alkaline phos 
phatase precursor one min after the chase. A faint band 
corresponding to the precursor was also evident even after 
ten min (FIG. 3B). 
Under physiological conditions, the periplasmic space of 
E. coli is rather poor in disulfide isomerase activity, a 
function that is thought to be mediated primarily by DsbC 
(Bardwell, 1994). Since a major role of PDI in the endo 
plasmic reticulum appears to be the catalysis of disulfide 
bond isomerization (Bardwell and Beckwith, 1993; Wittrup, 
1995), it was reasoned that the presence of rPDI in the E. coli 
periplasm may facilitate the expression of heterologous 
proteins whose folding requires the rearrangement of disul 
fide bonds. The rate limiting step in the in vitro folding of 
BPTI (Creighton, 1992; Weissman and Kim, 1992; 
Goldenberg, 1992). In vitro, the presence of PDI modestly 
increases the rate of formation of two disulfide intermediates 
but greatly increases their rate of intramolecular rearrange 
ment (Weissman and Kim, 1993) and possibly direct oxi 
dation (Creighton et al., 1980). Expression of secreted BPTI 
in E. coli results in low levels of native protein and is 
accompanied by the accumulation of two disulfide interme 
diates in the periplasmic space (Ostermeier and Georgiou, 
1994). To measure the effect of rPDI on BPTI expression, 
cells were co-transformed with p PPsOmpArPDI and 
pACYCBPTI, a compatible plasmid carrying the BPTI gene. 
The cells were grown in minimal media Supplemented with 
chloramphenicol and Amp to maintain both plasmids. 
Because the standard assay for BPTI, which is based on 
trypsin inhibition, is not very Sensitive and Suffers in part 
from interference from endogenous proteases and trypsin 
inhibitors, BPTI was quantified by ELISA using a primary 
polyclonal antibody raised against native BPTI. 
Coexpression of rPDI in wild type cells resulted in a six 
fold increase in BPTI in the absence of glutathione and a 
fifteen fold increase in its presence (FIG. 4). The increased 
yield with rPDI coexpression was not due to a higher rate of 
BPTI synthesis. If anything, co-expression of rPDI resulted 
in a slightly lower rate of BPTI synthesis as determined by 
radiolabeling Studies. This slight reduction in the rate of 
protein Synthesis cannot account for the increased efficiency 
of native BPTI formation since in the absence of rPDI, BPTI 
production was not found to improve in cells where the 
synthesis of BPTI was reduced by lowering the amount of 
inducer, IPTG. 
To confirm that the increased level of BPTI detected by 
ELISA was due to the production of native protein, BPTI 
was affinity precipitated with trypsin immobilized on agar 
ose beads and detected by Western blotting. The interaction 
between trypsin and native BPTI is exceedingly strong 
(dissociation constant 6x10' M) and the complex is stable 
for weeks at 4°C. (Vincent and Lazdunski, 1972). Reduced, 
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carboxymethylated BPTI does not bind to trypsin. Coo 
massie Staining of trypsin-precipitated Samples from Wild 
type cells not bearing any plasmid detected a band at 
approximately 16-kDa, the molecular weight of the E. coli 
trypsin inhibitor ecotin which has no homology with BPTI 
(McGrath et al., 1991). Several other faint bands were also 
visible, but none of these bands crossreacted with anti-BPTI 
sera on Western blots (FIG. 5A, lane 2). When such E. coli 
extracts were spiked with high levels of purified BPTI and 
trypsin affinity precipitated more than one band was detected 
by Western blotting (FIG.5A and FIG. 5B). At lower protein 
loading, however, only a single band was visible. 
Western blots showing the level of BPTI in wild type, 
dsbA and dsbB cultures, with or without co-expression of 
rPDI, and in the presence of various amounts of reduced or 
oxidized glutathione are shown in FIG. 5A and FIG. 5B. 
These studies confirmed that coexpression of rPDI increases 
the level of native BPTI production several fold and that 
production could be further enhanced by Supplementing the 
growth media with moderate amounts of GSH. In the 
absence of rPDI co-expression, glutathione alone did not 
increase the production of BPTI. A modest increase was 
Somewhat variable. The presence of high concentrations of 
GSH (25 mM) was found to adversely affect the production 
of BPTI both with and without rPDI co-expression. 
Cells lacking a functional DsbA or DsbB were found to be 
completely impaired in BPTI production, a deficiency which 
could not be alleviated by the addition of reduced or 
oxidized glutathione or a mixture thereof (FIG. 5B). 
Although exogenous oxidized glutathione can partially oxi 
dize DsbA and thus complement Some of the phenotypes of 
dsbB mutants, in this case it was not Sufficient to rescue 
BPTI production. Coexpression of rPDI was able to restore 
BPTI production in dsbA mutants but not disbB mutants, 
further illustrating that rPDI complements the dsbA muta 
tion and that rPDI’s oxidase activity is dependent on a 
functional DsbB protein. In disbB mutants, BPTI was 
detected only in cells coexpressing rPDI and Supplemented 
with 10 mM oxidized glutathione. The addition of 10 mM 
cyStamine to cultures expressing rPDI could also comple 
ment the disbB mutation. Since PDI has been shown to have 
a specificity for glutathione in forming the mixed disulfide 
in dithiol-mediated oxidation (Darby et al., 1994), these 
results Suggest that the likely role of the added dithiols is to 
oxidize the active site of rPDI which then carries out direct 
oxidation of the protein substrate. Finally, is should be 
mentioned that 10 mM oxidized DTT, which is a much 
weaker oxidizer that GSSG or cystamine, could not rescue 
BPTI disbB mutants coexpressing rPDI. 
In mutant cells, particularly disbB mutants, the induction 
of rPDI resulted in the accumulation of two higher molecu 
lar weight Species, one of which migrated with an electro 
phoretic mobility identical to the BPTI precursor. Both of 
these species were recognized by an antiserum against BPTI 
obtained from a different laboratory and are unlikely to 
represent croSSreacting E. coli proteins. AS was discussed 
above, the expression of rPDI in disbB mutants results in 
Some retardation of precursor processing. Therefore, it is 
possible that the higher molecular weight Species detected in 
the disbB mutants where rPDI was overproduced correspond 
to preCompa-BPTI species. Such preOmpA-BPTI species 
must contain at least Some of the native disulfides Since 
otherwise they could not have been bound by the immobi 
lized trypsin. 
To elucidate the role of PDI in the folding of BPTI, the 
kinetics of folding were monitored in pulse chase Studies 











cysteines with iodoacetamide and Separated by non 
reducing gel electrophoresis. In the electrophoretic System 
used here, all two-disulfide intermediates (designated as ) 
are well resolved from the native protein and from other 
folding species (Ostermeier and Georgiou, 1994). Without 
coexpressing rPDI, these two disulfide intermediates accu 
mulate during folding, and the rate limiting Step in the 
formation of native protein is their isomerization. In cells 
expressing rPDI, two disulfide intermediates were still 
observed to accumulate (FIG. 6). Furthermore, when 
reduced glutathione is added to the cells two disulfide 
intermediates accumulated to an even greater extent. In this 
case over 50% of the BPTI is found as two-disulfide 
intermediate Species after 20 min of chase. It appears that 
under these conditions rPDI in the E. coli periplasm did not 
have a noticeable effect on the rearrangement and/or direct 
oxidation of kinetically trapped two-disulfide intermediates. 
The exact fate of the * band is not known at present, but it 
must be degraded and/or eventually fold to native protein. 
When lysates of wild type cells or disbA mutants expressing 
rPDI (which had been labeled with "C-L-amino acids for 5 
hours and protein free cysteines blocked with 100 mM 
iodoacetamide) were immunoprecipitated and resolved on 
non-reducing Reisfeld-Urea gels, only native BPTI with 
three disulfides was found to be present. 
In cells co-expressing rPDI the half-life for the formation 
of the native protein was approximately 6–7 min indepen 
dent of whether GSH/GSSG had been added. This is experi 
mentally indistinguishable from the rate of BPTI folding 
without rPDI (Ostermeier and Georgiou, 1994) and consis 
tent with rPDI not having an effect on the rate limiting step: 
disulfide isomerization. For comparison, the folding of BPTI 
in eukaryotic microSomes, which are rich in PDI, can occur 
with a half life of less than one min at 30° C. and is 
accompanied by relatively little accumulation of two 
disulfide intermediates, depending on the redox conditions 
employed (Creighton et al., 1993). 
Rat protein disulfide isomerase is expressed at a high level 
in the E. coli periplasm even in dsbA mutants. Besides 
restoring normal growth in minimal media, expression of 
rPDI restores conjugation competence and Sensitivity to 
filamentous phages. These phenotypes are dependent on the 
presence of correctly assembled F pili, a process which is 
impaired when disulfide bond formation is compromised in 
dsbA mutants. Ostensibly, rPDI restores pili assembly by 
facilitating disulfide bond formation. Indeed, rPDI could 
catalyze the oxidation of native E. coli proteins Such as 
alkaline phosphatase and OmpA in cells lacking DsbA, 
albeit at a rate Somewhat slower than DsbAs. 
Although these results strongly Suggest that rPDI func 
tions as a cysteine oxidase in the periplasmic Space of 
gram-negative bacteria, another explanation is that rPDI 
does not function catalytically, but instead it Somehow 
induces the Synthesis of other E coli proteins that are 
responsible for disulfide bond formation. For example, Mis 
siakaset al. (1994) have shown that overexpression of DsbC 
can complement dsbA mutations and it may be possible that 
the phenomenon observed arose indirectly due to the induc 
tion of DsbC. This is not the case for the following reasons: 
(a) The oxidation of alkaline phosphatase in disbA mutants 
expressing rPDI is dependent on DsbB. However, high 
levels of DsbC in fact complement disbB mutations 
(Missiakas et al., 1994). Thus, the function of rPDI cannot 
merely be due to the induction of DsbC since then it would 
not be expected to be disbB dependent. (b) As shown in FIG. 
5A and FIG. 5B and discussed further below, expression of 
rPDI is essential for the formation of native BPTI in disbA 
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mutants. In the absence of rPDI, no BPTI is formed in disbA 
mutants even when the cells are grown with a wide range of 
concentrations of exogenous thiols and disulfides. Thus it 
cannot be argued that rPDI simply changes the redox State 
of the periplasm; rather its enzymatic activity per Se cata 
lyzes the formation of disulfide bonds in BPTI. 
Given the presence of millimolar concentrations of glu 
tathione in the ER (Hwang et al., 1992) and PDI’s specificity 
for glutathione (Darby et al., 1994) it appears that in 
eukaryotes the active state of PDI is maintained by glu 
tathione. Since there is no evidence for the presence of 
glutathione or other low molecular weight thiols in the 
bacterial periplasmic space (Wilfing and Pluckthun, 1994), 
it is reasonable to assume that for rPDI to be functional in 
the periplasm, it must be able to interact directly with a 
component of the prokaryotic disulfide forming machinery. 
Indeed, the rPDI-mediated formation of disulfide bonds in 
alkaline phosphatase and BPTI was found to be dependent 
on DsbB. This is interesting given that rPDI, apart from its 
thioredoxin active site, shows little homology to DsbA or to 
other bacterial proteins. It may be that the active site of rPDI, 
whose three dimensional Structure has not yet been Solved, 
conforms to the thioredoxin fold as is the case with DsbA. 
If the active sites of the two proteins are structurally similar, 
then it is reasonable to expect that a protein Such as DsbB, 
which normally interacts with DsbA, may also be able to 
interact with rPDI. Alternatively, rPDI’s dependence on 
DsbB may be an indirect effect. 
In catalytic amounts and in the presence of glutathionc or 
other small molecular weight thiols, PDI primarily catalyzes 
the formation of mixed disulfides with model peptide Sub 
strates (Darby et al., 1994). However, the lack of a periplas 
mic low molecular weight redox couple in bacteria and 
rPDI’s dependence on DsbB implies that rPDI catalyzes 
disulfide bond formation by direct transfer of its own 
disulfide bonds to protein substrates. Direct formation of 
disulfide bonds form PDI to reduced proteins has been 
observed in vitro with stoichiometric quantities of the 
enzyme and in the absence of other oxidants (Darby et al., 
1994; Zapun and Creighton, 1994). It should be noted that 
DsbA also normally transfers its disulfide bond directly to 
reduced protein substrates (Zapun and Creighton, 1994), but 
unlike with PDI, this reaction is not enhanced by the 
addition of glutathione redox buffers (Joly and Swartz, 
1994). 
Gram-negative bacterial proteins fold faster under very 
oxidizing conditions. For example, the optimal rate for 
folding of alkaline phosphatase in vitro occurs in 6 mM 
GSSG and proceeds at 50% the maximal rate in 30 mM 
GSSG (Walker and Gilbert, 1994). Accordingly, there is 
evidence that the periplasmic space is indeed highly oxidiz 
ing environment. Most, if not all, of the DsbA molecules 
have been shown to be in the oxidized form in the periplasm 
of wild type cells (Kishigami et al., 1995). The highly 
oxidized State of the periplasm can in part explain why 
eukaryotic proteins containing multiple disulfides are often 
poorly expressed. In the endoplasmic reticulum, these pro 
teins normally fold in a relatively reduced environment 
which affords the opportunity for reduction of incorrect 
disulfides and disulfide rearrangement, processes catalyzed 
by PDI (Freedman et al., 1994; Wittrup, 1995). Disulfide 
bond isomerization is likely to be relatively unimportant to 
E. coli as periplasmic and outer membrane proteins with 
more than two disulfides are rare (Joly and Swartz, 1994). 
For rPDI to be efficient in the oxidation of alkaline 
phosphatase in dsbA mutants, it must provide a redox 











equivalent (GSH/(GSSG) equilibrium constant of around 
20 uM (Walker and Gilbert, 1994). The redox potential of 
PDI at near physiological pH is equivalent to GSH/ 
GSSG) of around 40-80 uM. Thus, a significant fraction, if 
not the majority, of the rPDI molecules in the periplasm 
must be present in the oxidized form in order to effectively 
facilitate disulfide formation. This is quite different from the 
endoplasmic reticulum where the redox State is believed to 
be GSH/GSSG)=0.5–3.3 mM and PDI would be present 
almost exclusively in reduced form (Hwang et al., 1992). 
To examine whether rPDI can catalyze disulfide bond 
isomerization in the periplasm, the oxidative folding of 
BPTI was monitored. BPTI is a three disulfide protease 
inhibitor which is very poorly expressed in E. coil and 
whose in vitro folding pathway involves disulfide rearrange 
ment as shown in Scheme 1 (Goldenberg, 1992). 
PDI has been shown to catalyze virtually all of the steps 
in the in vitro folding pathway of BPTI (Weissman and Kim, 
1993; Creighton et al., 1980). In the presence of catalytic 
amounts of protein disulfide isomerase and a Suitable redox 
buffer, the rate of formation of N' and N* from reduced 
protein is increased by about three-fold whereas the Subse 
quent folding of these two kinetically trapped intermediates 
to N is accelerated by more than 3,000 fold (Weissman and 
Kim, 1993) resulting in a dramatic decrease in the amount 
of two disulfide intermediates observed during folding. 
Catalysis also appears to occur in Vivo as evidenced by the 
fact that relatively small amounts of two disulfide interme 
diates were detected during the folding of BPTI in 
microsomes (Creighton et al., 1993). 
Co-expression of rPDI in wild type E. coli increased the 
steady-state level of BPTI by fifteen fold in the presence of 
glutathione and six fold in its absence. However, pulse chase 
studies revealed that the presence of rPDI does not decrease 
the accumulation of two-disulfide intermediates. In fact, in 
the presence of glutathione, two disulfide intermediates 
accumulated to a greater extent. Thus, in wild type E. coli, 
rPDI does not facilitate the isomerization of N' and N* to 
N' anymore than the formation of N' and N*. 
In wild type cells, rPDI does not function as an appre 
ciable isomerase or direct oxidant of the final disulfide in the 
two disulfide intermediates, the rate limiting Step in folding. 
rPDIS apparent lack of isomerase activity in the periplasm 
is not Surprising Since evidence Suggests that the active Sites 
of rPDI in the periplasm are predominantly oxidized and 
therefore can only catalyze direct oxidation and not disulfide 
rearrangement. Attempts to improve BPTI production in 
Vivo by making the periplasm more reducing (i.e., by adding 
reducing agents or by using disb mutants) in order to elicit 
rPDI isomerase activity were unsuccessful, but should not 
be construed as evidence of an inability of rPDI to exhibit 
isomerase activity in the periplasm. In a more reducing 
periplasm, the rates of formation of the first and Second 
disulfides in BPTI should decrease and thus the competing 
process of proteolysis is likely to limit the yield of correctly 
folded protein. It may be that the conditions for eliciting 
rPDIS isomerase activity leave the periplasm too reducing 
for any BPTI molecules to efficiently form disulfides in 
order to avoid proteolysis. 
The increase in two disulfide intermediates with added 
glutathione indicates that rPDI is functioning as an oxidase 
that Supplements DsbA in forming the two disulfide inter 
mediates. In vitro, PDI’s oxidase activity has been found to 
be enhanced by the addition of a redox buffer of glutathione 
(Darby et al., 1994). 
Increased steady state levels of BPTI appear to be the 
result of the faster formation of two disulfide intermediates 
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from reduced protein thus avoiding proteolysis. It is also 
conceivable that the chaperon-like activity of PDI may play 
a role in the increased levels of BPTI (Puig and Gilbert, 
1994; Cai et al., 1994). Studies have determine the effect of 
PDI mutants with (a) only chaperon activity and (b) prima 
rily isomerase activity on the folding of BPTI in order to 
further elucidate the mechanism by which its co-expression 
facilitates the production of multi-disulfide containing pro 
teins. 
5.2 EXAMPLE 2-METHODS FOR EXPRESSION OF TPAIN BAC 
TERIAL CELLS 
This example describes the production of Soluble, active, 
secreted tRA in bacterial host cells by the co-expression of 
rPDI. Remarkably, rPDI coexpressed with rtPA significantly 
increases yields of tRA in the bacterial host cell. 
Strains RB791 and UT5600 were co-transformed with a 
pACYC184 derivative vector expressing tPA from the phoA 
promoter and with a pBR322 recombinant vector carrying a 
transcriptional unit comprising the PDI gene expressed 
downstream from either the lac-lpp or the PA promoter 
(Guzman et al., 1995). The latter construct was designated 
pBAD-StII-tPA. 
Expression of the two proteins was induced by the addi 
tion of inducers, IPTG, and arabinose, as appropriate. The 
cells were harvested after overnight growth and the level of 
tPA was determined by three methods. 
In the first method, a calorimetric assay was used in which 
the rate of plasmin formation from plasminogen was mea 
Sured (American Diagnostics, Inc.). The Second method was 
the fibrin plate assay, in which tRA-containing cell extracts 
were spotted on agar plates containing fibrin and plasmino 
gen and the Zone of clearance was determined. Finally, in the 
third method, Western blots were performed using anti-tPA 
antibodies. 
Active tRA was detected by both the fibrin plate assay and 
by the plasmin activation assay in cells co-expressing PDI. 
The level of active tRA protein was between about 5 and 
about 12 tug/L/ODoo units of protein depending upon the 
Strain background and particular growth conditions used. 
Importantly, practically no active tFA could be detected in 
cultures that did not co-express PDI. The co-expression of 
PDI increased the amount of Soluble, active tRA, but did not 
affect the total amount (soluble--insoluble) detected by West 
ern blotting. 
5.3 EXAMPLE 3–CLONING AND EXPRESSION OF THE YEAST 
PDI IN E. COLI 
The mature yeast PDI sequence was cloned by PCRTM 
amplification of the gene from an S. cerevisiae cDNA library 
(obtained from Professor K.D. Wittrup, Department of 
Chemical Engineering, University of Illinois, Urbana 
Champaign) using the following primers: GG 18: 
5ATATGAATTCTGGTTTTCGCCCAACAAGAAGCT 
GTGGCC-3' (SEQ. ID NO. : 1) and GG 28: 
5-'GGACGGAGGATCCTTACAATTCATGGTG-3' (SEQ. 
ID: 2). 
The amplified DNA product contains a Xbal and BamHI 
restriction sites allowing the insertion of the gene into the 
expression vector pG105 (Grayeb et al., 1984). The result 
ing plasmid was designated pLpplac-YPDI-I. In plpplac 
YPDI-1 the yeast PDI gene is fused in frame to the Ompa 
leader peptide. The omp A-ypdi gene is downstream from a 
strong ribosomal binding site and the IPTG-inducible lipp 
lac promoter. plpplac-YPDI-1 was transformed into a vari 
ety of E. coli strains including RB791, R189 and R190 
(Bardwell etal., 1991). Induction ofypdi syntheses by IPTG 
resulted in Somewhat Slower growth. A band corresponding 
to the full length yeast PDI was detected by Western blotting 











The plpplac-YPDI-1 plasmid and pG105 as a control 
were transformed in the disbA and disbA strains R189 and 
R190, respectively (FIG. 8). dsbA mutant cells do not 
express alkaline phosphatase activity. Expression of the rat 
PDI in E. coli restores alkaline phosphatase activity in 
dsbA mutants and a similar effect was seen in cells trans 
formed with plpplac-YPDI-1 and inducted with IPTG. 
Thus, the yeast PDI is functional when expressed in bacteria 
and can complement the defect in dsbA cells. In Separate 
studies, RB791 cells were transformed with pACYCBPTI 
and pLpplac-YPDI-1. Induction of BPTI and yPDI with 0.5 
MMIPTG resulted in f-fold higher specific BPTI levels (per 
mg of total Soluble protein) compared to cells that did not 
coexpress the yeast PDI. Importantly, unlike the case with 
rate PDI, the effect of years PDI could not be improved 
further by the additional of reductants Such as glutathione. 
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All of the compositions and methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be 
apparent to those of Skill in the art that variations may be 
applied to the composition, methods and in the Steps or in the 
Sequence of Steps of the method described herein without 
departing from the concept, Spirit and Scope of the invention. 
More specifically, it will be apparent that certain agents 
which are both chemically and physiologically related may 
be substituted for the agents described herein while the same 
or similar results would be achieved. All Such similar 
Substitutes and modifications apparent to those skilled in the 
art are deemed to be within the Spirit, Scope and concept of 
the invention as defined by the appended claims. 
Accordingly, the exclusive rights Sought to be patented are 




<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<400 SEQUENCE: 1 
atatgaattic toggtttitcgc ccaacaagaa gotgtggcc 
SEQ ID NO 2 
LENGTH 2.8 
TYPE DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
Primer 
<400 SEQUENCE: 2 
ggacggagga to cittacaat tdatggtg 
What is claimed is: 
1. A process for producing in a bacterial cell, a 
biologically-active, Soluble eukaryotic polypeptide having 
at least about three disulfide bonds, comprising expressing 
in Said cell a first DNA segment encoding a disulfide 
isomerase operably linked to a signal Sequence and a Second 
DNA segment encoding Said eukaryotic polypcptide oper 
ably linked to a signal Sequence under conditions effective 
to produce Said eukaryotic polypeptide. 
2. The process according to claim 1, wherein Said Signal 
Sequence is Selected from the group consisting of Omp A, 
LamB, StII, MalE, Lpp, and PelB. 
3. The process according to claim 1, wherein Said first and 
Said Second DNA segments are expressed from one or more 
promoters Selected from the group consisting of lac-lipp, lac, 
ara, lipp, tre, tac, T7, PAP, phoA and 2 p. 
4. The process according to claim 1, wherein Said first 
DNA segment is expressed by plPPsOmp ArPDI, or 
wherein Said Second DNA segment is expressed by 
pTPA177 or pACYCBPTI. 
5. The process according to claim 1, wherein Said eukary 
otic polypeptide is Secreted to the periplasm or to the outer 
membrane of Said bacterial cell. 
6. The process according to claim 1, wherein Said eukary 
otic polypeptide is isolatable from a culture Supernatant or a 
Soluble fraction of said bacterial cell. 
7. The process according to claim 1, wherein Said eukary 
otic polypeptide produced in Said bacterial host cell has the 
Same conformation assumed by Said polypeptide when pro 
duced in a eukaryotic host cell. 
8. The process according to claim 1, wherein Said eukary 
otic polypeptide is a mammalian polypeptide. 
9. The process according to claim 8, wherein Said mam 
malian polypeptide is a human or bovine polypeptide. 
10. The process according to claim 9, wherein said 
mammalian polypeptide is a tissue plasminogen activator or 
pancreatic trypsin inhibitor. 
11. The process according to claim 1, wherein Said 
disulfide isomerase is protein disulfide isomerase. 
12. The process according to claim 11, wherein Said 
protein disulfide isomerase is a rat, yeast, or human protein 
disulfide isomerase. 
13. The process according to claim 1, wherein Said 
eukaryotic polypeptide comprises at least Seven disulfide 
bonds. 
14. The process according to claim 13, wherein Said 
eukaryotic polypeptide comprises at least twelve disulfide 
bonds. 













15. The process according to claim 14, wherein Said 
eukaryotic polypeptide comprises at least fourteen disulfide 
bonds. 
16. The process according to claim 15, wherein Said 
eukaryotic polypeptide comprises at least Seventeen disul 
fide bonds. 
17. The process according to claim 16, wherein Said 
eukaryotic polypeptide comprises Seventeen disulfide 
bonds. 
18. The process according to claim 1, wherein Said 
bacterial cell is an Escherichia coli or Salmonella spp. cell. 
19. The process according to claim 18, wherein said 
bacterial cell is cultured in a medium comprising one or 
more reducing agents Selected from the group consisting of 
glutathione, cysticine, cyStamine, thioglycollate, 
dithioerythritol, dithiothreitol and dithioerythritol. 
20. The process according to claim 18, wherein said 
Escherichia coli cell is Selected from the group consisting of 
ATCC 98380, SF103, SF110, UT5600 and RB791. 
21. The process according to claim 1, wherein Said 
eukaryotic polypeptide produced in Said bacterial cell has a 
Specific activity equal to or greater than the Specific activity 
of Said polypeptide when produced in a eukaryotic host cell. 
22. The process according to claim 21, wherein Said 
eukaryotic polypeptide is a tissue plasminogen activator 
protein or a pancreatic trypsin inhibitor protein having a 
specific activity of at least about 1 to about 30 
Aug/L/ODoo of culture. 
23. An expression System for producing in a bacterial cell, 
a biologically-active, Soluble eukaryotic polypeptide, Said 
System comprising a first DNA segment and a Second DNA 
Segment, wherein Said first Segment encodes a disulfide 
isomerase and Said Second Segment encodes a eukaryotic 
polypeptide having at least about three disulfide bonds. 
24. The expression System according to claim 23, wherein 
said first DNA segment is expressed by pl PPsOmpArPDI or 
wherein Said Second DNA segment is expressed by 
pTPA177 or pACYCBPTI. 
25. The expression System according to claim 23, wherein 
Said E. coli cell is Selected from the group consisting of 
ATCC 98380, SF103, SF110, UT5600 and RB791. 
26. The expression System according to claim 23, wherein 
Said eukaryotic polypeptide is a mammalian polypeptide. 
27. The expression System according to claim 26, wherein 




28. The expression System according to claim 27, wherein 
Said mammalian polypeptide is a tissue plasminogen acti 
Vator or pancreatic trypsin inhibitor. 
29. The expression System according to claim 23, wherein 
Said disulfide isomerase is protein disulfide isomerase. 
30. The expression system according to claim 29, wherein 
Said protein disulfide isomerase is Selected from the group 
consisting of rat, yeast, and human protein disulfide 
isomerase. 
31. The expression System according to claim 23, wherein 
said first DNA segment or said second DNA segment further 
comprises a Signal Sequence Selected from the group con 
sisting of Omp A, LamB, StI, MalE, Lipp, and PelB. 
32. The expression System according to claim 31, wherein 
Said Signal Sequence is an OmpA Signal Sequence. 
33. The expression System according to claim 23, wherein 
said first DNA segment or said second DNA segment is 
expressed from one or more promoters Selected from the 
group consisting of lac-lpp, lac, ara, lpp, trc, tac, T7, PA, 
phoA and 2. 
34. The expression System according to claim 33, wherein 
said first DNA segment or said second DNA segment is 
expressed from a lac-lpp promoter. 
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35. A recombinant vector comprising a first transcrip 
tional unit encoding a mammalian protein disulfide 
isomerase operably linked to a first Signal Sequence and Said 
Second transcriptional unit comprises a DNA segment 
encoding a mammalian polypeptide having at least about 
three disulfide bonds operably linked to a Second Signal 
Sequence. 
36. The recombinant vector according to claim 35, 
wherein Said mammalian polypeptide is a human or bovine 
polypeptide. 
37. The recombinant vector according to claim 35, 
wherein Said mammalian polypeptide is a tissue plasmino 
gen activator or pancreatic trypsin inhibitor. 
38. The recombinant vector according to claim 35, 
wherein Said protein disulfide isomerase is a rat, yeast, or 
human protein disulfide isomerase. 
39. A prokaryotic cell transformed with the vector accord 
ing to claim 35. 
40. The cell of claim 39, further defined as E. coli ATCC 
98.380. 
